,AID,AID Version,AID Revision,Panel Member ID,SID,CID,Bioactivity Outcome,Target GI,Target GeneID,Activity Value [uM],Activity Name,Assay Name,Bioassay Type,PubMed ID,RNAi
0,200,1,1,,71484,6228,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  B16 Melanoma (intraperitoneal) in B6C3F1 mice,Other,,
1,206,1,1,,71484,6228,Active,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  HT29;CX-1 Human Adenocarcinoma (MER+) (intrarenal inoculation) in NU/NU Swiss (nude) mice,Other,,
2,210,1,1,,71484,6228,Active,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Colon 26 Adenocarcinoma (intraperitoneal) in CD2F1 (CDF1) mice,Other,,
3,212,1,1,,71484,6228,Inconclusive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Colon Carcinoma 38 (subcutaneous) in B6D2F1 (BDF1) mice,Other,,
4,220,1,1,,71484,6228,Inconclusive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Mammary Adenocarcinoma CD8F1 (subcutaneous) in CD8F1,Other,,
5,226,1,1,,71484,6228,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Ependymoblastoma (intracerebral) in B6C3F1 mice,Other,,
6,256,1,1,,71484,6228,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  L1210 Leukemia (intraperitoneal) in CD2F1 (CDF1) mice,Other,,
7,264,1,1,,71484,6228,Inconclusive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Human Lung LX-1 Xenograft (intrarenal inoculation) in NU/NU Swiss (nude) mice,Other,,
8,292,1,1,,71484,6228,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Sarcoma M5076 (intraperitoneal) in B6C3F1 mice,Other,,
9,294,1,1,,71484,6228,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Human Mammary Carcinoma MX-1 Xenograft (subcutaneous) in NU/NU Swiss (nude) mice,Other,,
10,296,1,1,,71484,6228,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Human Mammary Carcinoma MX-1 Xenograft (intrarenal inoculation) in NU/NU Swiss (nude) mice,Other,,
11,302,1,1,,71484,6228,Active,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Madison 109 Lung Carcinoma (intramuscular) in BALB/CM mice,Other,,
12,330,1,1,,71484,6228,Inconclusive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  P388 Leukemia (intraperitoneal) in CD2F1 (CDF1) mice,Other,,
13,421,1,3,,17388882,6228,Inactive,,,,,Cell Viability - BJ,Confirmatory,,
14,421,1,3,,17389908,6228,Inactive,,,,,Cell Viability - BJ,Confirmatory,,
15,426,1,2,,17388882,6228,Inactive,,,,,Cell Viability - Jurkat,Confirmatory,,
16,426,1,2,,17389908,6228,Inactive,,,,,Cell Viability - Jurkat,Confirmatory,,
17,427,1,1,,17388882,6228,Inactive,,,,,Cell Viability - Hek293,Confirmatory,,
18,427,1,1,,17389908,6228,Inactive,,,,,Cell Viability - Hek293,Confirmatory,,
19,433,1,1,,17388882,6228,Inactive,,,,,Cell Viability - HepG2,Confirmatory,,
20,433,1,1,,17389908,6228,Inactive,,,,,Cell Viability - HepG2,Confirmatory,,
21,434,1,2,,17388882,6228,Inactive,,,,,Cell Viability - MRC5,Confirmatory,,
22,434,1,2,,17389908,6228,Inactive,,,,,Cell Viability - MRC5,Confirmatory,,
23,435,1,2,,17388882,6228,Inactive,,,,,Cell Viability - SK-N-SH,Confirmatory,,
24,435,1,2,,17389908,6228,Inactive,,,,,Cell Viability - SK-N-SH,Confirmatory,,
25,445,3,1,,17388882,6228,Inactive,10092619.0,4792.0,,,IkB Signaling,Confirmatory,,
26,445,3,1,,17389908,6228,Inactive,10092619.0,4792.0,,,IkB Signaling,Confirmatory,,
27,530,1,1,,17388882,6228,Inactive,2499604.0,26414.0,,,JNK3 AlphaScreen Assay,Confirmatory,,
28,530,1,1,,17389908,6228,Inactive,2499604.0,26414.0,,,JNK3 AlphaScreen Assay,Confirmatory,,
29,540,1,1,,17388882,6228,Inactive,,,,,Cell Viability - N2a,Confirmatory,,
30,540,1,1,,17389908,6228,Inactive,,,,,Cell Viability - N2a,Confirmatory,,
31,541,1,1,,17388882,6228,Inactive,,,,,Cell Viability - NIH 3T3,Confirmatory,,
32,541,1,1,,17389908,6228,Inactive,,,,,Cell Viability - NIH 3T3,Confirmatory,,
33,542,1,1,,17388882,6228,Inactive,,,,,Cell Viability - HUV-EC-C,Confirmatory,,
34,542,1,1,,17389908,6228,Inactive,,,,,Cell Viability - HUV-EC-C,Confirmatory,,
35,543,1,1,,17388882,6228,Inactive,,,,,Cell Viability - H-4-II-E,Confirmatory,,
36,543,1,1,,17389908,6228,Inactive,,,,,Cell Viability - H-4-II-E,Confirmatory,,
37,544,2,1,,17388882,6228,Inactive,,,,,Cell Viability - SH-SY5Y,Confirmatory,,
38,544,2,1,,17389908,6228,Inactive,,,,,Cell Viability - SH-SY5Y,Confirmatory,,
39,545,1,1,,17388882,6228,Inactive,,,,,Cell Viability - Renal Proximal Tubule,Confirmatory,,
40,545,1,1,,17389908,6228,Inactive,,,,,Cell Viability - Renal Proximal Tubule,Confirmatory,,
41,546,1,1,,17388882,6228,Inactive,,,,,Cell Viability - Mesenchymal,Confirmatory,,
42,546,1,1,,17389908,6228,Inactive,,,,,Cell Viability - Mesenchymal,Confirmatory,,
43,584,1,3,,17388882,6228,Inactive,119389684.0,,,,Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay with detergent),Confirmatory,,
44,584,1,3,,17389908,6228,Inactive,119389684.0,,,,Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay with detergent),Confirmatory,,
45,585,1,4,,17388882,6228,Inactive,119389684.0,,,,Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay without detergent),Confirmatory,,
46,585,1,4,,17389908,6228,Inactive,119389684.0,,,,Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay without detergent),Confirmatory,,
47,595,1,3,,17388882,6228,Inactive,,,,,qHTS Assay for Disrupters of an Hsp90 Co-Chaperone Interaction,Confirmatory,,
48,595,1,3,,17389908,6228,Inactive,,,,,qHTS Assay for Disrupters of an Hsp90 Co-Chaperone Interaction,Confirmatory,,
49,596,1,2,,17388882,6228,Inactive,92096784.0,4137.0,,,qHTS Assay for Tau Filament Binding,Confirmatory,,
50,596,1,2,,17389908,6228,Inactive,92096784.0,4137.0,,,qHTS Assay for Tau Filament Binding,Confirmatory,,
51,603,1,2,,17388882,6228,Inactive,,,,,qHTS Assay for Inhibitors of DNA Polymerase III Holoenzyme System,Confirmatory,,
52,603,1,2,,17389908,6228,Inactive,,,,,qHTS Assay for Inhibitors of DNA Polymerase III Holoenzyme System,Confirmatory,,
53,605,1,2,,17388882,6228,Inactive,84028058.0,,,,qHTS Assay for Inhibitors of YjeE,Confirmatory,,
54,605,1,2,,17389908,6228,Inactive,84028058.0,,,,qHTS Assay for Inhibitors of YjeE,Confirmatory,,
55,654,1,1,,17388882,6228,Inactive,,,,,Cellular Toxicity (caspase-3) HepG2,Confirmatory,,
56,654,1,1,,17389908,6228,Inactive,,,,,Cellular Toxicity (caspase-3) HepG2,Confirmatory,,
57,655,1,1,,17388882,6228,Inactive,,,,,Cellular Toxicity (caspase-3) Jurkat,Confirmatory,,
58,655,1,1,,17389908,6228,Inactive,,,,,Cellular Toxicity (caspase-3) Jurkat,Confirmatory,,
59,656,1,1,,17388882,6228,Inactive,,,,,Cellular Toxicity (caspase-3) HUV-EC-C,Confirmatory,,
60,656,1,1,,17389908,6228,Inactive,,,,,Cellular Toxicity (caspase-3) HUV-EC-C,Confirmatory,,
61,657,1,1,,17388882,6228,Inactive,,,,,Cellular Toxicity (caspase-3) SHSY5Y,Confirmatory,,
62,657,1,1,,17389908,6228,Inactive,,,,,Cellular Toxicity (caspase-3) SHSY5Y,Confirmatory,,
63,658,1,1,,17388882,6228,Inactive,,,,,Cellular Toxicity (caspase-3) BJ,Confirmatory,,
64,658,1,1,,17389908,6228,Inactive,,,,,Cellular Toxicity (caspase-3) BJ,Confirmatory,,
65,659,1,1,,17388882,6228,Inactive,,,,,Cellular Toxicity (caspase-3) MRC-5,Confirmatory,,
66,659,1,1,,17389908,6228,Inactive,,,,,Cellular Toxicity (caspase-3) MRC-5,Confirmatory,,
67,660,1,1,,17388882,6228,Inactive,,,,,Cellular Toxicity (caspase-3) Mesangial,Confirmatory,,
68,660,1,1,,17389908,6228,Inactive,,,,,Cellular Toxicity (caspase-3) Mesangial,Confirmatory,,
69,661,1,1,,17388882,6228,Inactive,,,,,Cellular Toxicity (caspase-3) SK-N-SH,Confirmatory,,
70,661,1,1,,17389908,6228,Inactive,,,,,Cellular Toxicity (caspase-3) SK-N-SH,Confirmatory,,
71,662,1,1,,17388882,6228,Inactive,,,,,Cell signaling CRE-BLA (Fsk stim),Confirmatory,,
72,662,1,1,,17389908,6228,Inactive,,,,,Cell signaling CRE-BLA (Fsk stim),Confirmatory,,
73,663,1,1,,17388882,6228,Inactive,,,,,Cellular Toxicity (caspase-3) H-4-II-E,Confirmatory,,
74,663,1,1,,17389908,6228,Inactive,,,,,Cellular Toxicity (caspase-3) H-4-II-E,Confirmatory,,
75,664,1,1,,17388882,6228,Inactive,,,,,Cellular Toxicity (caspase-3) Hek293,Confirmatory,,
76,664,1,1,,17389908,6228,Inactive,,,,,Cellular Toxicity (caspase-3) Hek293,Confirmatory,,
77,665,1,1,,17388882,6228,Inactive,,,,,Cellular Toxicity (caspase-3) N2a,Confirmatory,,
78,665,1,1,,17389908,6228,Inactive,,,,,Cellular Toxicity (caspase-3) N2a,Confirmatory,,
79,666,1,1,,17388882,6228,Inactive,,,,,Cellular Toxicity (caspase-3) NIH 3T3,Confirmatory,,
80,666,1,1,,17389908,6228,Inactive,,,,,Cellular Toxicity (caspase-3) NIH 3T3,Confirmatory,,
81,667,1,1,,17388882,6228,Inactive,,,,,Cellular Toxicity (caspase-3) Renal Proximal Tubule,Confirmatory,,
82,667,1,1,,17389908,6228,Inactive,,,,,Cellular Toxicity (caspase-3) Renal Proximal Tubule,Confirmatory,,
83,875,1,2,,17388882,6228,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Green Fluorophore),Confirmatory,,
84,875,1,2,,17389908,6228,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Green Fluorophore),Confirmatory,,
85,880,2,1,,17388882,6228,Inactive,3290016.0,6002.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
86,880,2,1,,17388882,6228,Inactive,33946324.0,2770.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
87,880,2,1,,17389908,6228,Inactive,3290016.0,6002.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
88,880,2,1,,17389908,6228,Inactive,33946324.0,2770.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
89,881,2,2,,17388882,6228,Inactive,317373425.0,247.0,,Potency,qHTS Assay for Inhibitors of 15-hLO-2 (15-human lipoxygenase 2),Confirmatory,,
90,881,2,2,,17389908,6228,Inactive,317373425.0,247.0,,Potency,qHTS Assay for Inhibitors of 15-hLO-2 (15-human lipoxygenase 2),Confirmatory,,
91,884,1,2,,17388882,6228,Inactive,13435386.0,1576.0,,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 3A4,Confirmatory,,
92,884,1,2,,17389908,6228,Inactive,13435386.0,1576.0,,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 3A4,Confirmatory,,
93,885,1,2,,17388882,6228,Inactive,13435386.0,1576.0,,Potency,qHTS Assay for Activators of Cytochrome P450 3A4,Confirmatory,,
94,885,1,2,,17389908,6228,Inactive,13435386.0,1576.0,,Potency,qHTS Assay for Activators of Cytochrome P450 3A4,Confirmatory,,
95,886,1,2,,17388882,6228,Inactive,122921310.0,,,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
96,886,1,2,,17388882,6228,Inactive,122921311.0,,,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
97,886,1,2,,17389908,6228,Inactive,122921310.0,,,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
98,886,1,2,,17389908,6228,Inactive,122921311.0,,,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
99,887,1,2,,17388882,6228,Inactive,1832253.0,246.0,,Potency,qHTS Assay for Inhibitors of 15-hLO (15-human lipoxygenase),Confirmatory,,
100,887,1,2,,17389908,6228,Inactive,1832253.0,246.0,,Potency,qHTS Assay for Inhibitors of 15-hLO (15-human lipoxygenase),Confirmatory,,
101,889,1,3,,17388882,6228,Inactive,1730092.0,840.0,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-7,Confirmatory,,
102,889,1,3,,17389908,6228,Inactive,1730092.0,840.0,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-7,Confirmatory,,
103,892,1,2,,17388882,6228,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Red Fluorophore),Confirmatory,,
104,892,1,2,,17389908,6228,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Red Fluorophore),Confirmatory,,
105,893,1,2,,17388882,6228,Inactive,122921310.0,,,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
106,893,1,2,,17388882,6228,Inactive,122921311.0,,,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
107,893,1,2,,17389908,6228,Inactive,122921310.0,,,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
108,893,1,2,,17389908,6228,Inactive,122921311.0,,,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
109,894,2,1,,17388882,6228,Inactive,31542939.0,3248.0,,Potency,qHTS Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase),Confirmatory,,
110,894,2,1,,17389908,6228,Inactive,31542939.0,3248.0,,Potency,qHTS Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase),Confirmatory,,
111,900,1,3,,17388882,6228,Inactive,15431328.0,834.0,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1,Confirmatory,,
112,900,1,3,,17389908,6228,Inactive,15431328.0,834.0,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1,Confirmatory,,
113,902,1,2,,17388882,6228,Inactive,120407068.0,7157.0,,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature,Confirmatory,,
114,902,1,2,,17389908,6228,Inactive,120407068.0,7157.0,,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature,Confirmatory,,
115,912,1,2,,17388882,6228,Inactive,21392848.0,,,Potency,qHTS Assay for Anthrax Lethal Toxin Internalization,Confirmatory,,
116,912,1,2,,17389908,6228,Inactive,21392848.0,,,Potency,qHTS Assay for Anthrax Lethal Toxin Internalization,Confirmatory,,
117,921,1,2,,17388882,6228,Inactive,,,,Potency,Cell Viability - LYMP2-001,Confirmatory,,
118,921,1,2,,17389908,6228,Inactive,,,,Potency,Cell Viability - LYMP2-001,Confirmatory,,
119,923,1,2,,17388882,6228,Inactive,,,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1: Spectroscopic Profiling in AFC Spectral Region,Confirmatory,,
120,923,1,2,,17389908,6228,Inactive,,,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1: Spectroscopic Profiling in AFC Spectral Region,Confirmatory,,
121,924,1,2,,17388882,6228,Inactive,120407068.0,7157.0,,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature,Confirmatory,,
122,924,1,2,,17389908,6228,Inactive,120407068.0,7157.0,,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature,Confirmatory,,
123,925,1,2,,17388882,6228,Inactive,4504349.0,3043.0,,Potency,qHTS Assay for Modulators of Hemoglobin Beta Chain Splicing,Confirmatory,,
124,925,1,2,,17389908,6228,Inactive,4504349.0,3043.0,,Potency,qHTS Assay for Modulators of Hemoglobin Beta Chain Splicing,Confirmatory,,
125,926,1,2,,17388882,6228,Inactive,38016895.0,7253.0,,Potency,qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor,Confirmatory,,
126,926,1,2,,17389908,6228,Inconclusive,38016895.0,7253.0,0.0398,Potency,qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor,Confirmatory,,
127,938,1,2,,17388882,6228,Inactive,38016895.0,7253.0,,Potency,qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor: Activators of Intracellular cAMP Concentrations in Parental HEK 293,Confirmatory,,
128,938,1,2,,17389908,6228,Inconclusive,38016895.0,7253.0,0.0398,Potency,qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor: Activators of Intracellular cAMP Concentrations in Parental HEK 293,Confirmatory,,
129,946,1,2,,17388882,6228,Inactive,,,,Potency,MultiTox-Fluor Cytotoxicity Assay - LYMP1-001 - Dead Cells,Confirmatory,,
130,946,1,2,,17389908,6228,Inactive,,,,Potency,MultiTox-Fluor Cytotoxicity Assay - LYMP1-001 - Dead Cells,Confirmatory,,
131,947,1,2,,17388882,6228,Inactive,,,,Potency,MultiTox-Fluor Cytotoxicity Assay - LYMP1-001 - Live Cells,Confirmatory,,
132,947,1,2,,17389908,6228,Inconclusive,,,5.0119,Potency,MultiTox-Fluor Cytotoxicity Assay - LYMP1-001 - Live Cells,Confirmatory,,
133,948,1,2,,17388882,6228,Inactive,,,,Potency,Cell Viability - LYMP1-002 - Assay at 16 hr,Confirmatory,,
134,948,1,2,,17389908,6228,Inactive,,,,Potency,Cell Viability - LYMP1-002 - Assay at 16 hr,Confirmatory,,
135,955,1,2,,17388882,6228,Inactive,,,,Potency,MultiTox-Fluor Cytotoxicity Assay - LYMP1-002 - Live Cells,Confirmatory,,
136,955,1,2,,17389908,6228,Inactive,,,,Potency,MultiTox-Fluor Cytotoxicity Assay - LYMP1-002 - Live Cells,Confirmatory,,
137,960,1,2,,17388882,6228,Inactive,,,,Potency,MultiTox-Fluor Cytotoxicity Assay - LYMP1-002 - Dead Cells,Confirmatory,,
138,960,1,2,,17389908,6228,Inactive,,,,Potency,MultiTox-Fluor Cytotoxicity Assay - LYMP1-002 - Dead Cells,Confirmatory,,
139,961,1,2,,17388882,6228,Inactive,,,,Potency,MultiTox-Fluor Cytotoxicity Assay - LYMP1-003 - Dead Cells,Confirmatory,,
140,961,1,2,,17389908,6228,Inactive,,,,Potency,MultiTox-Fluor Cytotoxicity Assay - LYMP1-003 - Dead Cells,Confirmatory,,
141,962,1,2,,17388882,6228,Inactive,,,,Potency,MultiTox-Fluor Cytotoxicity Assay - LYMP1-003 - Live Cells,Confirmatory,,
142,962,1,2,,17389908,6228,Inactive,,,,Potency,MultiTox-Fluor Cytotoxicity Assay - LYMP1-003 - Live Cells,Confirmatory,,
143,963,1,2,,17388882,6228,Inactive,,,,Potency,Cell Viability - LYMP1-003 - Assay at 24 hr,Confirmatory,,
144,963,1,2,,17389908,6228,Inactive,,,,Potency,Cell Viability - LYMP1-003 - Assay at 24 hr,Confirmatory,,
145,964,1,2,,17388882,6228,Inactive,,,,Potency,Cell Viability - LYMP1-003 - Assay at 40 hr,Confirmatory,,
146,964,1,2,,17389908,6228,Inactive,,,,Potency,Cell Viability - LYMP1-003 - Assay at 40 hr,Confirmatory,,
147,965,1,2,,17388882,6228,Inactive,,,,Potency,Cell Viability - LYMP2-003,Confirmatory,,
148,965,1,2,,17389908,6228,Inactive,,,,Potency,Cell Viability - LYMP2-003,Confirmatory,,
149,966,1,2,,17388882,6228,Inactive,,,,Potency,Cell Viability - LYMP2-004,Confirmatory,,
150,966,1,2,,17389908,6228,Inactive,,,,Potency,Cell Viability - LYMP2-004,Confirmatory,,
151,967,1,2,,17388882,6228,Inactive,,,,Potency,Cell Viability - LYMP2-005,Confirmatory,,
152,967,1,2,,17389908,6228,Inactive,,,,Potency,Cell Viability - LYMP2-005,Confirmatory,,
153,968,1,2,,17388882,6228,Inactive,,,,Potency,Cell Viability - LYMP2-009,Confirmatory,,
154,968,1,2,,17389908,6228,Inactive,,,,Potency,Cell Viability - LYMP2-009,Confirmatory,,
155,969,1,2,,17388882,6228,Inactive,,,,Potency,Cell Viability - LYMP2-011,Confirmatory,,
156,969,1,2,,17389908,6228,Inactive,,,,Potency,Cell Viability - LYMP2-011,Confirmatory,,
157,970,1,2,,17388882,6228,Inactive,,,,Potency,Cell Viability - LYMP2-013,Confirmatory,,
158,970,1,2,,17389908,6228,Inactive,,,,Potency,Cell Viability - LYMP2-013,Confirmatory,,
159,971,1,2,,17388882,6228,Inactive,,,,Potency,Cell Viability - LYMP2-015,Confirmatory,,
160,971,1,2,,17389908,6228,Inactive,,,,Potency,Cell Viability - LYMP2-015,Confirmatory,,
161,972,1,2,,17388882,6228,Inactive,,,,Potency,Cell Viability - LYMP2-017,Confirmatory,,
162,972,1,2,,17389908,6228,Inactive,,,,Potency,Cell Viability - LYMP2-017,Confirmatory,,
163,973,1,2,,17388882,6228,Inactive,,,,Potency,Cell Viability - LYMP2-019,Confirmatory,,
164,973,1,2,,17389908,6228,Inactive,,,,Potency,Cell Viability - LYMP2-019,Confirmatory,,
165,974,1,2,,17388882,6228,Inactive,,,,Potency,Cell Viability - LYMP2-021,Confirmatory,,
166,974,1,2,,17389908,6228,Inactive,,,,Potency,Cell Viability - LYMP2-021,Confirmatory,,
167,975,1,2,,17388882,6228,Inactive,,,,Potency,Cell Viability - LYMP2-023,Confirmatory,,
168,975,1,2,,17389908,6228,Inactive,,,,Potency,Cell Viability - LYMP2-023,Confirmatory,,
169,976,1,2,,17388882,6228,Inactive,,,,Potency,Cell Viability - LYMP2-025,Confirmatory,,
170,976,1,2,,17389908,6228,Inactive,,,,Potency,Cell Viability - LYMP2-025,Confirmatory,,
171,977,1,2,,17388882,6228,Inactive,,,,Potency,Cell Viability - LYMP2-002,Confirmatory,,
172,977,1,2,,17389908,6228,Inactive,,,,Potency,Cell Viability - LYMP2-002,Confirmatory,,
173,978,1,2,,17388882,6228,Inactive,,,,Potency,Cell Viability - LYMP2-006,Confirmatory,,
174,978,1,2,,17389908,6228,Inactive,,,,Potency,Cell Viability - LYMP2-006,Confirmatory,,
175,979,1,2,,17388882,6228,Inactive,,,,Potency,Cell Viability - LYMP2-007,Confirmatory,,
176,979,1,2,,17389908,6228,Inactive,,,,Potency,Cell Viability - LYMP2-007,Confirmatory,,
177,980,1,2,,17388882,6228,Inactive,,,,Potency,Cell Viability - LYMP2-008,Confirmatory,,
178,980,1,2,,17389908,6228,Inactive,,,,Potency,Cell Viability - LYMP2-008,Confirmatory,,
179,981,1,2,,17388882,6228,Inactive,,,,Potency,Cell Viability - LYMP2-010,Confirmatory,,
180,981,1,2,,17389908,6228,Inactive,,,,Potency,Cell Viability - LYMP2-010,Confirmatory,,
181,982,1,2,,17388882,6228,Inactive,,,,Potency,Cell Viability - LYMP2-012,Confirmatory,,
182,982,1,2,,17389908,6228,Inactive,,,,Potency,Cell Viability - LYMP2-012,Confirmatory,,
183,983,1,2,,17388882,6228,Inactive,,,,Potency,Cell Viability - LYMP2-014,Confirmatory,,
184,983,1,2,,17389908,6228,Inactive,,,,Potency,Cell Viability - LYMP2-014,Confirmatory,,
185,984,1,2,,17388882,6228,Inactive,,,,Potency,Cell Viability - LYMP2-016,Confirmatory,,
186,984,1,2,,17389908,6228,Inactive,,,,Potency,Cell Viability - LYMP2-016,Confirmatory,,
187,985,1,2,,17388882,6228,Inactive,,,,Potency,Cell Viability - LYMP2-018,Confirmatory,,
188,985,1,2,,17389908,6228,Inactive,,,,Potency,Cell Viability - LYMP2-018,Confirmatory,,
189,986,1,2,,17388882,6228,Inactive,,,,Potency,Cell Viability - LYMP2-020,Confirmatory,,
190,986,1,2,,17389908,6228,Inactive,,,,Potency,Cell Viability - LYMP2-020,Confirmatory,,
191,987,1,2,,17388882,6228,Inactive,,,,Potency,Cell Viability - LYMP2-022,Confirmatory,,
192,987,1,2,,17389908,6228,Inactive,,,,Potency,Cell Viability - LYMP2-022,Confirmatory,,
193,988,1,2,,17388882,6228,Inactive,,,,Potency,Cell Viability - LYMP2-024,Confirmatory,,
194,988,1,2,,17389908,6228,Inactive,,,,Potency,Cell Viability - LYMP2-024,Confirmatory,,
195,989,1,2,,17388882,6228,Inactive,,,,Potency,Cell Viability - LYMP2-026,Confirmatory,,
196,989,1,2,,17389908,6228,Inactive,,,,Potency,Cell Viability - LYMP2-026,Confirmatory,,
197,993,1,2,,17388882,6228,Inactive,,,,Potency,Cell Viability - LYMP1-002 - Assay at 24 hr,Confirmatory,,
198,993,1,2,,17389908,6228,Inactive,,,,Potency,Cell Viability - LYMP1-002 - Assay at 24 hr,Confirmatory,,
199,994,1,2,,17388882,6228,Inactive,,,,Potency,Cell Viability - LYMP1-002 - Assay at 40 hr,Confirmatory,,
200,994,1,2,,17389908,6228,Inactive,,,,Potency,Cell Viability - LYMP1-002 - Assay at 40 hr,Confirmatory,,
201,995,1,2,,17388882,6228,Inactive,66932916.0,5594.0,,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay,Confirmatory,,
202,995,1,2,,17389908,6228,Inactive,66932916.0,5594.0,,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay,Confirmatory,,
203,1030,2,1,,17388882,6228,Inactive,30582681.0,216.0,,Potency,qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1),Confirmatory,,
204,1030,2,1,,17389908,6228,Inactive,30582681.0,216.0,,Potency,qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1),Confirmatory,,
205,1189,1,5,,48413664,6228,Inactive,,,,,DSSTox (CPDBAS) Carcinogenic Potency Database Summary SingleCellCall Results,Other,,
206,1194,1,3,,48413664,6228,Inactive,,,,,DSSTox (CPDBAS) Carcinogenic Potency Database Salmonella Mutagenicity,Other,,
207,1199,1,3,,48413664,6228,Inactive,,,,,DSSTox (CPDBAS) Carcinogenic Potency Database Summary Mouse Bioassay Results,Other,,
208,1205,1,4,,48413664,6228,Inactive,,,,,DSSTox (CPDBAS) Carcinogenic Potency Database Summary MultiCellCall Results,Other,,
209,1208,1,3,,48413664,6228,Inactive,,,,,DSSTox (CPDBAS) Carcinogenic Potency Database Summary Rat Bioassay Results,Other,,
210,1452,1,1,,17388882,6228,Inactive,154426292.0,239.0,,Potency,qHTS Assay for Inhibitors of 12-hLO (12-human lipoxygenase),Confirmatory,,
211,1452,1,1,,17389908,6228,Inactive,154426292.0,239.0,,Potency,qHTS Assay for Inhibitors of 12-hLO (12-human lipoxygenase),Confirmatory,,
212,1457,1,1,,17388882,6228,Inconclusive,44888968.0,83523.0,6.3096,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium,Confirmatory,,
213,1457,1,1,,17389908,6228,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium,Confirmatory,,
214,1458,1,1,,17388882,6228,Inactive,10937869.0,6607.0,,Potency,qHTS Assay for Enhancers of SMN2 Splice Variant Expression,Confirmatory,,
215,1458,1,1,,17389908,6228,Inactive,10937869.0,6607.0,,Potency,qHTS Assay for Enhancers of SMN2 Splice Variant Expression,Confirmatory,,
216,1469,1,1,,17388882,6228,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
217,1469,1,1,,17389908,6228,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
218,1469,1,1,,26752801,6228,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
219,1471,2,1,,17388882,6228,Inactive,90903231.0,3064.0,,,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP),Confirmatory,,
220,1471,2,1,,17389908,6228,Inactive,90903231.0,3064.0,,,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP),Confirmatory,,
221,1476,2,1,,17388882,6228,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (without detergent),Confirmatory,,
222,1476,2,1,,17389908,6228,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (without detergent),Confirmatory,,
223,1477,1,1,,17388882,6228,Inactive,,,,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia,Confirmatory,,
224,1477,1,1,,17389908,6228,Inactive,,,,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia,Confirmatory,,
225,1478,2,1,,17388882,6228,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (with detergent),Confirmatory,,
226,1478,2,1,,17389908,6228,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (with detergent),Confirmatory,,
227,1479,1,2,,17388882,6228,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
228,1479,1,2,,17389908,6228,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
229,1479,1,2,,26752801,6228,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
230,1948,1,1,,17388882,6228,Inactive,,,,Potency,qHTS Assay for Compounds that Induce Erasure of Genomic Imprints,Confirmatory,,
231,1948,1,1,,17389908,6228,Inactive,,,,Potency,qHTS Assay for Compounds that Induce Erasure of Genomic Imprints,Confirmatory,,
232,2101,1,1,,17388882,6228,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
233,2101,1,1,,17389908,6228,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
234,2107,1,1,,17388882,6228,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
235,2107,1,1,,17389908,6228,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
236,2112,1,1,,17388882,6228,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
237,2112,1,1,,17389908,6228,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
238,2120,1,1,,17388882,6228,Inactive,32879895.0,3091.0,,Potency,qHTS Assay for Identification of Small Molecule Inducers of Hypoxia Response,Confirmatory,,
239,2120,1,1,,17389908,6228,Inactive,32879895.0,3091.0,,Potency,qHTS Assay for Identification of Small Molecule Inducers of Hypoxia Response,Confirmatory,,
240,2517,2,1,,17388882,6228,Inactive,6980812.0,,,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
241,2517,2,1,,17389908,6228,Inactive,6980812.0,,,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
242,2546,1,1,,17388882,6228,Inactive,188536040.0,19885.0,,Potency,VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
243,2546,1,1,,17389908,6228,Inactive,188536040.0,19885.0,,Potency,VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
244,2549,1,1,,17388882,6228,Inactive,282403581.0,,,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
245,2549,1,1,,17389908,6228,Inactive,282403581.0,,,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
246,2551,1,1,,17388882,6228,Inactive,188536040.0,19885.0,,Potency,qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
247,2551,1,1,,17389908,6228,Inactive,188536040.0,19885.0,,Potency,qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
248,110145,3,4,,103168637,6228,Unspecified,,,,,Antitumor activity was evaluated against the M5076 reticulum cell sarcoma in mice measured as Control tumor volume for the treated at the optimal dose 1000 mg/Kg/day,Other,3712373.0,
249,116701,3,4,,103168637,6228,Unspecified,,,,,Antitumor activity was evaluated against the M5076 reticulum cell sarcoma in mice at dose of 1500-600 mg/kg per day,Other,3712373.0,
250,116885,4,2,,103168637,6228,Unspecified,,,,,Antitumor activity was evaluated against the M5076 reticulum cell sarcoma in mice at dose of 1500-600 mg/kg per day,Other,3712373.0,
251,118807,3,4,,103168637,6228,Unspecified,,,,,Antitumor activity was evaluated against the M5076 reticulum cell sarcoma in mice measured as mean tumor volume for the treated at the optimal dose 1000 mg/Kg/day,Other,3712373.0,
252,122265,3,4,,103168637,6228,Unspecified,,,,,Antitumor activity was evaluated for the compound against the M5076 reticulum cell sarcoma in mice and the % T/C(treated/control) value was calculated at optimal dose of 1000 mg/kg,Other,3712373.0,
253,159270,4,1,,103168637,6228,Unspecified,,,301995000000.0,EC50,Toxicity determined using Microtox Test,Confirmatory,2033592.0,
254,386832,4,2,,103168637,6228,Unspecified,,,,,Antibacterial activity against Escherichia coli at 100 ug/mL after 48 hrs by cup-plate method,Other,17959273.0,
255,386833,4,2,,103168637,6228,Unspecified,,,,,Antibacterial activity against Escherichia coli at 50 ug/mL after 48 hrs by cup-plate method,Other,17959273.0,
256,386834,4,2,,103168637,6228,Unspecified,,,,,Antibacterial activity against Escherichia coli at 25 ug/mL after 48 hrs by cup-plate method,Other,17959273.0,
257,386835,4,2,,103168637,6228,Unspecified,,,,,Antibacterial activity against Bacillus cirrhosis at 100 ug/mL after 48 hrs by cup-plate method,Other,17959273.0,
258,386836,4,2,,103168637,6228,Unspecified,,,,,Antibacterial activity against Bacillus cirrhosis at 50 ug/mL after 48 hrs by cup-plate method,Other,17959273.0,
259,386837,4,2,,103168637,6228,Unspecified,,,,,Antibacterial activity against Bacillus cirrhosis at 25 ug/mL after 48 hrs by cup-plate method,Other,17959273.0,
260,386838,4,2,,103168637,6228,Unspecified,,,,,Antifungal activity against Aspergillus niger at 100 ug/mL after 48 hrs by cup-plate method,Other,17959273.0,
261,386839,4,2,,103168637,6228,Unspecified,,,,,Antifungal activity against Aspergillus niger at 50 ug/mL after 48 hrs by cup-plate method,Other,17959273.0,
262,386840,4,2,,103168637,6228,Unspecified,,,,,Antifungal activity against Aspergillus niger at 25 ug/mL after 48 hrs by cup-plate method,Other,17959273.0,
263,386841,4,2,,103168637,6228,Unspecified,,,,,Antifungal activity against Rhizoctonia bataticola at 100 ug/mL after 48 hrs by cup-plate method,Other,17959273.0,
264,386842,4,2,,103168637,6228,Unspecified,,,,,Antifungal activity against Rhizoctonia bataticola at 50 ug/mL after 48 hrs by cup-plate method,Other,17959273.0,
265,386843,4,2,,103168637,6228,Unspecified,,,,,Antifungal activity against Rhizoctonia bataticola at 25 ug/mL after 48 hrs by cup-plate method,Other,17959273.0,
266,476296,3,4,,103168637,6228,Unspecified,,,,,Antibacterial activity against Staphylococcus capitis ATCC 2784 assessed as decrease in survival at 0.5 M by turbidimetric method,Other,19896248.0,
267,476297,3,4,,103168637,6228,Unspecified,,,,,Antibacterial activity against Staphylococcus capitis ATCC 2784 assessed as decrease in survival at 1.3 M by turbidimetric method,Other,19896248.0,
268,485290,1,1,,17388882,6228,Inactive,20150581.0,,,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
269,485290,1,1,,17389908,6228,Inactive,20150581.0,,,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
270,588209,2,3,,103168637,6228,Unspecified,,,,,Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset,Other,20553011.0,
271,588513,1,1,,17388882,6228,Inactive,348019627.0,2099.0,,Potency,qHTS assay for small molecule antagonists of estrogen receptor alpha signaling,Confirmatory,,
272,588513,1,1,,17389908,6228,Inactive,348019627.0,2099.0,,Potency,qHTS assay for small molecule antagonists of estrogen receptor alpha signaling,Confirmatory,,
273,588513,1,1,,26752801,6228,Inactive,348019627.0,2099.0,,Potency,qHTS assay for small molecule antagonists of estrogen receptor alpha signaling,Confirmatory,,
274,588514,1,1,,17388882,6228,Inactive,348019627.0,2099.0,,Potency,qHTS assay for small molecule agonists of estrogen receptor alpha signaling,Confirmatory,,
275,588514,1,1,,17389908,6228,Inactive,348019627.0,2099.0,,Potency,qHTS assay for small molecule agonists of estrogen receptor alpha signaling,Confirmatory,,
276,588514,1,1,,26752801,6228,Inactive,348019627.0,2099.0,,Potency,qHTS assay for small molecule agonists of estrogen receptor alpha signaling,Confirmatory,,
277,588515,1,1,,17388882,6228,Inactive,124375976.0,367.0,,Potency,qHTS assay for small molecule agonists of androgen receptor signaling,Confirmatory,,
278,588515,1,1,,17389908,6228,Inactive,124375976.0,367.0,,Potency,qHTS assay for small molecule agonists of androgen receptor signaling,Confirmatory,,
279,588515,1,1,,26752801,6228,Inactive,124375976.0,367.0,,Potency,qHTS assay for small molecule agonists of androgen receptor signaling,Confirmatory,,
280,588516,1,1,,17388882,6228,Inactive,124375976.0,367.0,,Potency,qHTS assay for small molecule antagonists of androgen receptor signaling,Confirmatory,,
281,588516,1,1,,17389908,6228,Inconclusive,124375976.0,367.0,,Potency,qHTS assay for small molecule antagonists of androgen receptor signaling,Confirmatory,,
282,588516,1,1,,26752801,6228,Inactive,124375976.0,367.0,,Potency,qHTS assay for small molecule antagonists of androgen receptor signaling,Confirmatory,,
283,588526,1,1,,17388882,6228,Inactive,325495553.0,9971.0,,Potency,qHTS assay for small molecule antagonists of farnesoid X receptor signaling,Confirmatory,,
284,588526,1,1,,17389908,6228,Inactive,325495553.0,9971.0,,Potency,qHTS assay for small molecule antagonists of farnesoid X receptor signaling,Confirmatory,,
285,588526,1,1,,26752801,6228,Inactive,325495553.0,9971.0,,Potency,qHTS assay for small molecule antagonists of farnesoid X receptor signaling,Confirmatory,,
286,588527,1,1,,17388882,6228,Inactive,325495553.0,9971.0,,Potency,qHTS assay for small molecule agonists of farnesoid X receptor signaling,Confirmatory,,
287,588527,1,1,,17389908,6228,Inactive,325495553.0,9971.0,,Potency,qHTS assay for small molecule agonists of farnesoid X receptor signaling,Confirmatory,,
288,588527,1,1,,26752801,6228,Inactive,325495553.0,9971.0,,Potency,qHTS assay for small molecule agonists of farnesoid X receptor signaling,Confirmatory,,
289,588532,1,1,,17388882,6228,Inactive,311348376.0,2908.0,,Potency,qHTS assay for small molecule agonists of glucocorticoid receptor signaling,Confirmatory,,
290,588532,1,1,,17389908,6228,Inactive,311348376.0,2908.0,,Potency,qHTS assay for small molecule agonists of glucocorticoid receptor signaling,Confirmatory,,
291,588532,1,1,,26752801,6228,Inconclusive,311348376.0,2908.0,0.0141,Potency,qHTS assay for small molecule agonists of glucocorticoid receptor signaling,Confirmatory,,
292,588533,1,1,,17388882,6228,Inactive,311348376.0,2908.0,,Potency,qHTS assay for small molecule antagonists of glucocorticoid receptor signaling,Confirmatory,,
293,588533,1,1,,17389908,6228,Inactive,311348376.0,2908.0,,Potency,qHTS assay for small molecule antagonists of glucocorticoid receptor signaling,Confirmatory,,
294,588533,1,1,,26752801,6228,Inactive,311348376.0,2908.0,,Potency,qHTS assay for small molecule antagonists of glucocorticoid receptor signaling,Confirmatory,,
295,588534,1,1,,17388882,6228,Inactive,216409690.0,5467.0,,Potency,qHTS assay for small molecule agonists of peroxisome proliferator-activated receptor delta signaling,Confirmatory,,
296,588534,1,1,,17389908,6228,Inactive,216409690.0,5467.0,,Potency,qHTS assay for small molecule agonists of peroxisome proliferator-activated receptor delta signaling,Confirmatory,,
297,588534,1,1,,26752801,6228,Inactive,216409690.0,5467.0,,Potency,qHTS assay for small molecule agonists of peroxisome proliferator-activated receptor delta signaling,Confirmatory,,
298,588535,1,1,,17388882,6228,Inactive,216409690.0,5467.0,,Potency,qHTS assay for small molecule antagonists of peroxisome proliferator-activated receptor delta signaling,Confirmatory,,
299,588535,1,1,,17389908,6228,Inconclusive,216409690.0,5467.0,,Potency,qHTS assay for small molecule antagonists of peroxisome proliferator-activated receptor delta signaling,Confirmatory,,
300,588535,1,1,,26752801,6228,Inactive,216409690.0,5467.0,,Potency,qHTS assay for small molecule antagonists of peroxisome proliferator-activated receptor delta signaling,Confirmatory,,
301,588536,1,1,,17388882,6228,Inactive,216409692.0,5468.0,,Potency,qHTS assay for small molecule agonists of peroxisome proliferator-activated receptor gamma signaling,Confirmatory,,
302,588536,1,1,,17389908,6228,Inactive,216409692.0,5468.0,,Potency,qHTS assay for small molecule agonists of peroxisome proliferator-activated receptor gamma signaling,Confirmatory,,
303,588536,1,1,,26752801,6228,Inactive,216409692.0,5468.0,,Potency,qHTS assay for small molecule agonists of peroxisome proliferator-activated receptor gamma signaling,Confirmatory,,
304,588537,1,1,,17388882,6228,Inconclusive,216409692.0,5468.0,,Potency,qHTS assay for small molecule antagonists of peroxisome proliferator-activated receptor gamma signaling,Confirmatory,,
305,588537,1,1,,17389908,6228,Inactive,216409692.0,5468.0,,Potency,qHTS assay for small molecule antagonists of peroxisome proliferator-activated receptor gamma signaling,Confirmatory,,
306,588537,1,1,,26752801,6228,Inactive,216409692.0,5468.0,,Potency,qHTS assay for small molecule antagonists of peroxisome proliferator-activated receptor gamma signaling,Confirmatory,,
307,588541,1,1,,17388882,6228,Inactive,216409708.0,7421.0,,Potency,qHTS assay for small molecule antagonists of vitamin D receptor signaling,Confirmatory,,
308,588541,1,1,,17389908,6228,Inactive,216409708.0,7421.0,,Potency,qHTS assay for small molecule antagonists of vitamin D receptor signaling,Confirmatory,,
309,588541,1,1,,26752801,6228,Inactive,216409708.0,7421.0,,Potency,qHTS assay for small molecule antagonists of vitamin D receptor signaling,Confirmatory,,
310,588543,1,1,,17388882,6228,Inactive,216409708.0,7421.0,,Potency,qHTS assay for small molecule agonists of vitamin D receptor signaling,Confirmatory,,
311,588543,1,1,,17389908,6228,Inactive,216409708.0,7421.0,,Potency,qHTS assay for small molecule agonists of vitamin D receptor signaling,Confirmatory,,
312,588543,1,1,,26752801,6228,Inactive,216409708.0,7421.0,,Potency,qHTS assay for small molecule agonists of vitamin D receptor signaling,Confirmatory,,
313,588544,1,1,,17388882,6228,Inactive,325495497.0,6256.0,,Potency,qHTS assay for small molecule agonists of retinoid X receptor alpha signaling,Confirmatory,,
314,588544,1,1,,17389908,6228,Inactive,325495497.0,6256.0,,Potency,qHTS assay for small molecule agonists of retinoid X receptor alpha signaling,Confirmatory,,
315,588544,1,1,,26752801,6228,Active,325495497.0,6256.0,14.1254,Potency,qHTS assay for small molecule agonists of retinoid X receptor alpha signaling,Confirmatory,,
316,588545,1,1,,17388882,6228,Inactive,189491771.0,7068.0,,Potency,qHTS assay for small molecule agonists of thyroid hormone receptor beta signaling,Confirmatory,,
317,588545,1,1,,17389908,6228,Inactive,189491771.0,7068.0,,Potency,qHTS assay for small molecule agonists of thyroid hormone receptor beta signaling,Confirmatory,,
318,588545,1,1,,26752801,6228,Inactive,189491771.0,7068.0,,Potency,qHTS assay for small molecule agonists of thyroid hormone receptor beta signaling,Confirmatory,,
319,588546,1,1,,17388882,6228,Inactive,325495497.0,6256.0,,Potency,qHTS assay for small molecule antagonists of retinoid X receptor alpha signaling,Confirmatory,,
320,588546,1,1,,17389908,6228,Inconclusive,325495497.0,6256.0,,Potency,qHTS assay for small molecule antagonists of retinoid X receptor alpha signaling,Confirmatory,,
321,588546,1,1,,26752801,6228,Inactive,325495497.0,6256.0,,Potency,qHTS assay for small molecule antagonists of retinoid X receptor alpha signaling,Confirmatory,,
322,588547,1,1,,17388882,6228,Inactive,189491771.0,7068.0,,Potency,qHTS assay for small molecule antagonists of thyroid hormone receptor beta signaling,Confirmatory,,
323,588547,1,1,,17389908,6228,Inactive,189491771.0,7068.0,,Potency,qHTS assay for small molecule antagonists of thyroid hormone receptor beta signaling,Confirmatory,,
324,588547,1,1,,26752801,6228,Inactive,189491771.0,7068.0,,Potency,qHTS assay for small molecule antagonists of thyroid hormone receptor beta signaling,Confirmatory,,
325,588834,2,1,,17388882,6228,Inactive,325651834.0,3757.0,,Potency,qHTS Assay for Small Molecule Inhibitors of the Human hERG Channel Activity,Confirmatory,,
326,588834,2,1,,17389908,6228,Inactive,325651834.0,3757.0,,Potency,qHTS Assay for Small Molecule Inhibitors of the Human hERG Channel Activity,Confirmatory,,
327,625144,5,5,,103168637,6228,Unspecified,239977155.0,,,IC50,DRUGMATRIX: Leukotriene LTC4 Synthase enzyme inhibition (substrate: LTA4),Confirmatory,,
328,625145,4,7,,103168637,6228,Unspecified,20138087.0,10800.0,,IC50,DRUGMATRIX: Cysteinyl leukotriene receptor 1 radioligand binding (ligand: [3H]LTD4),Confirmatory,,
329,625146,5,5,,103168637,6228,Unspecified,126397.0,100009114.0,,IC50,DRUGMATRIX: Lipoxygenase 15-LO enzyme inhibition (substrate: Linoleic acid),Confirmatory,,
330,625147,4,7,,103168637,6228,Unspecified,395398606.0,4159.0,,IC50,DRUGMATRIX: Melanocortin MC3 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
331,625148,4,7,,103168637,6228,Unspecified,60392672.0,4160.0,,IC50,DRUGMATRIX: Melanocortin MC4 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
332,625149,4,7,,103168637,6228,Unspecified,729996.0,4161.0,,IC50,DRUGMATRIX: Melanocortin MC5 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
333,625150,5,5,,103168637,6228,Unspecified,113978.0,4128.0,,IC50,DRUGMATRIX: Monoamine Oxidase MAO-A enzyme inhibition (substrate: Kynuramine),Confirmatory,,
334,625151,4,7,,103168637,6228,Unspecified,113118.0,1128.0,,IC50,DRUGMATRIX: Muscarinic M1 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
335,625152,4,7,,103168637,6228,Unspecified,113122.0,1129.0,,IC50,DRUGMATRIX: Muscarinic M2 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
336,625153,4,7,,103168637,6228,Unspecified,113125.0,1131.0,,IC50,DRUGMATRIX: Muscarinic M3 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
337,625154,4,7,,103168637,6228,Unspecified,23503039.0,1132.0,,IC50,DRUGMATRIX: Muscarinic M4 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
338,625155,4,7,,103168637,6228,Unspecified,543761.0,1133.0,,IC50,DRUGMATRIX: Muscarinic M5 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
339,625156,1,9,,103168637,6228,Unspecified,128997.0,4886.0,,,DRUGMATRIX: Neuropeptide Y Y1 radioligand binding (ligand: [125I] Peptide YY),Other,,
340,625157,6,2,,103168637,6228,Unspecified,1352610.0,4887.0,,IC50,DRUGMATRIX: Neuropeptide Y Y2 radioligand binding (ligand: [125I] Peptide YY),Confirmatory,,
341,625158,3,4,,103168637,6228,Unspecified,,,,IC50,DRUGMATRIX: Nicotinic Acetylcholine radioligand binding (ligand: [125I] Epibatidine),Confirmatory,,
342,625159,5,5,,103168637,6228,Unspecified,266646.0,24598.0,,IC50,"DRUGMATRIX: Nitric Oxide Synthase, Neuronal (nNOS) radioligand binding (ligand: [3H]L-Arginine)",Confirmatory,,
343,625160,1,9,,103168637,6228,Unspecified,266649.0,18126.0,,,"DRUGMATRIX: Nitric Oxide Synthase, Inducible (iNOS) enzyme inhibition (substrate: L-Arginine)",Other,,
344,625161,4,7,,103168637,6228,Unspecified,311033488.0,4985.0,,IC50,"DRUGMATRIX: Opiate delta1 (OP1, DOP) radioligand binding (ligand: [3H] Naltrindole)",Confirmatory,,
345,625162,4,7,,103168637,6228,Unspecified,116242691.0,4986.0,,IC50,"DRUGMATRIX: Opiate kappa (OP2, KOP) radioligand binding (ligand: [3H] Diprenorphine)",Confirmatory,,
346,625163,4,7,,103168637,6228,Unspecified,2851402.0,4988.0,,IC50,"DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine)",Confirmatory,,
347,625164,1,6,,103168637,6228,Unspecified,,,,,DRUGMATRIX: Phorbol Ester radioligand binding (ligand: [3H] PDBu),Other,,
348,625165,3,4,,103168637,6228,Unspecified,,,,IC50,DRUGMATRIX: Phosphodiesterase PDE3 enzyme inhibition (substrate: [3H]cAMP + cAMP),Confirmatory,,
349,625166,3,4,,103168637,6228,Unspecified,,,,IC50,DRUGMATRIX: Phosphodiesterase PDE4 enzyme inhibition (substrate: [3H]cAMP + cAMP),Confirmatory,,
350,625167,5,5,,103168637,6228,Unspecified,317373261.0,8654.0,,IC50,DRUGMATRIX: Phosphodiesterase PDE5 enzyme inhibition (substrate: [3H]cGMP + cGMP),Confirmatory,,
351,625168,4,7,,103168637,6228,Unspecified,129557.0,5724.0,,IC50,DRUGMATRIX: Platelet Activating Factor (PAF) radioligand binding (ligand: [3H] PAF),Confirmatory,,
352,625169,1,6,,103168637,6228,Unspecified,,,,,DRUGMATRIX: Platelet-Derived Growth Factor (PDGF) radioligand binding (ligand: [125I] PDGF),Other,,
353,625170,3,4,,103168637,6228,Unspecified,,,,IC50,DRUGMATRIX: Potassium Channel [KATP] radioligand binding (ligand: [3H] Glyburide),Confirmatory,,
354,625171,4,7,,103168637,6228,Unspecified,7531135.0,3757.0,,IC50,DRUGMATRIX: Potassium Channel HERG radioligand binding (ligand: [3H] Astemizole),Confirmatory,,
355,625172,4,7,,103168637,6228,Unspecified,75071465.0,,,IC50,DRUGMATRIX: Progesterone radioligand binding (ligand: [3H] R-5020),Confirmatory,,
356,625173,5,5,,103168637,6228,Unspecified,2822103.0,100009274.0,,IC50,"DRUGMATRIX: Peptidase, Angiotensin Converting Enzyme enzyme inhibition (substrate: FAPGG)",Confirmatory,,
357,625174,5,5,,103168637,6228,Unspecified,266321.0,834.0,,IC50,"DRUGMATRIX: Protease, Caspase 1 enzyme inhibition (substrate: Ac-YVAD-AMC)",Confirmatory,,
358,625175,5,5,,103168637,6228,Unspecified,115725.0,1511.0,,IC50,"DRUGMATRIX: Protease, Cathepsin G enzyme inhibition (substrate: Suc-Ala-Ala-Pro-Phe-AMC)",Confirmatory,,
359,625176,1,9,,103168637,6228,Unspecified,119292.0,1991.0,,,"DRUGMATRIX: Peptidase, ELA2 (Neutrophil Elastase 2) enzyme inhibition (substrate: N-MeOSuc-Ala-Ala-Pro-Val-pNA)",Other,,
360,625177,5,5,,103168637,6228,Unspecified,116852.0,4312.0,,IC50,"DRUGMATRIX: Peptidase, Matrix Metalloprotease-1 (MMP-1) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Confirmatory,,
361,625178,5,5,,103168637,6228,Unspecified,269849668.0,4318.0,,IC50,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Confirmatory,,
362,625179,1,9,,103168637,6228,Unspecified,317373571.0,5578.0,,,DRUGMATRIX: Protein Serine/Threonine Kinase PKCalpha enzyme inhibition (substrate: Histone),Other,,
363,625180,5,5,,103168637,6228,Unspecified,232066.0,5595.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, ERK1 enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
364,625181,5,5,,103168637,6228,Unspecified,119554.0,5594.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, ERK2 enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
365,625182,5,5,,103168637,6228,Unspecified,2499600.0,1432.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, p38alpha enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
366,625183,5,5,,103168637,6228,Unspecified,1352673.0,5530.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Phosphatase, PPP3CA (Calcineurin, PP2B) enzyme inhibition (substrate: DiFMUP)",Confirmatory,,
367,625184,5,5,,103168637,6228,Unspecified,2811086.0,1956.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
368,625185,5,5,,103168637,6228,Unspecified,125370.0,2534.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, Fyn enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
369,625186,5,5,,103168637,6228,Unspecified,119533.0,2064.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, ERBB2 (HER2) enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
370,625187,5,5,,103168637,6228,Unspecified,125474.0,3932.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, LCK enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
371,625188,1,9,,103168637,6228,Unspecified,33112650.0,5788.0,,,"DRUGMATRIX: Protein Tyrosine Phosphatase, PTPRC (CD45) enzyme inhibition (substrate: DiFMUP)",Other,,
372,625189,1,7,,103168637,6228,Unspecified,,,,,"DRUGMATRIX: Purinergic P2X radioligand binding (ligand: [3H] alpha, beta-Methylene-ATP)",Other,,
373,625190,4,5,,103168637,6228,Unspecified,,,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1A radioligand binding (ligand: [3H] 8-OH-DPAT),Confirmatory,,
374,625191,4,7,,103168637,6228,Unspecified,112815.0,25075.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1B radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
375,625192,4,7,,103168637,6228,Unspecified,543727.0,3356.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Confirmatory,,
376,625193,5,5,,103168637,6228,Unspecified,113037.0,43.0,,IC50,DRUGMATRIX: Acetylcholinesterase enzyme inhibition (substrate: acetylthiocholine),Confirmatory,,
377,625194,4,7,,103168637,6228,Unspecified,231473.0,134.0,,IC50,DRUGMATRIX: Adenosine A1 radioligand binding (ligand: DPCPX),Confirmatory,,
378,625195,4,7,,103168637,6228,Unspecified,543740.0,135.0,,IC50,DRUGMATRIX: Adenosine A2A radioligand binding (ligand: AB-MECA),Confirmatory,,
379,625196,5,6,,103168637,6228,Unspecified,803374855.0,140.0,,IC50,DRUGMATRIX: Adenosine A3 radioligand binding (ligand: AB-MECA),Confirmatory,,
380,625197,3,4,,103168637,6228,Unspecified,,,,IC50,DRUGMATRIX: Sodium/nucleoside co-transporter radioligand binding (ligand: nitrobenzylthioinosine),Confirmatory,,
381,625198,4,7,,103168637,6228,Unspecified,1168247.0,29412.0,,IC50,DRUGMATRIX: Alpha-1A adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
382,625199,4,7,,103168637,6228,Unspecified,543734.0,24173.0,,IC50,DRUGMATRIX: Alpha-1B adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
383,625200,4,7,,103168637,6228,Unspecified,1168243.0,146.0,,IC50,DRUGMATRIX: Alpha-1D adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
384,625201,4,7,,103168637,6228,Unspecified,1351829.0,150.0,,IC50,DRUGMATRIX: Alpha-2A adrenergic receptor radioligand binding (ligand: MK-912),Confirmatory,,
385,625202,4,7,,103168637,6228,Unspecified,613504690.0,151.0,,IC50,DRUGMATRIX: Alpha-2B adrenergic receptor radioligand binding (ligand: Rauwolscine),Confirmatory,,
386,625203,4,7,,103168637,6228,Unspecified,20141211.0,152.0,,IC50,DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912),Confirmatory,,
387,625204,4,7,,103168637,6228,Unspecified,48429211.0,153.0,,IC50,DRUGMATRIX: Adrenergic beta1 radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
388,625205,4,7,,103168637,6228,Unspecified,296439450.0,154.0,,IC50,DRUGMATRIX: Adrenergic beta2 radioligand binding (ligand: [3H] CGP-12177),Confirmatory,,
389,625206,4,7,,103168637,6228,Unspecified,461604.0,155.0,,IC50,DRUGMATRIX: Adrenergic beta3 radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
390,625207,4,7,,103168637,6228,Unspecified,128616.0,6530.0,,IC50,DRUGMATRIX: Norepinephrine Transporter radioligand binding (ligand: [125I] RTI-55),Confirmatory,,
391,625208,5,5,,103168637,6228,Unspecified,1168407.0,24192.0,,IC50,DRUGMATRIX: Aldose Reductase enzyme inhibition (substrate: DL-Glyceraldehyde),Confirmatory,,
392,625209,4,7,,103168637,6228,Unspecified,1703214.0,186.0,,IC50,DRUGMATRIX: Angiotensin AT2 radioligand binding (ligand: [125I] CGP-42112A),Confirmatory,,
393,625210,3,4,,103168637,6228,Unspecified,,,,IC50,"DRUGMATRIX: ATPase, Na+/K+ enzyme inhibition (substrate: ATP)",Confirmatory,,
394,625211,1,6,,103168637,6228,Unspecified,,,,,DRUGMATRIX: Atrial Natriuretic Factor (ANF) radioligand binding (ligand: [125I] ANF (rat)),Other,,
395,625212,3,4,,103168637,6228,Unspecified,,,,IC50,DRUGMATRIX: beta-Lactamase enzyme inhibition (substrate: Nitrocefin),Confirmatory,,
396,625213,4,7,,103168637,6228,Unspecified,2506481.0,624.0,,IC50,DRUGMATRIX: Bradykinin B2 radioligand binding (ligand: [3H] Bradykinin),Confirmatory,,
397,625214,1,9,,103168637,6228,Unspecified,550544247.0,799.0,,,DRUGMATRIX: Calcitonin radioligand binding (ligand: [125I] Calcitonin (salmon)),Other,,
398,625215,3,4,,103168637,6228,Unspecified,,,,IC50,"DRUGMATRIX: Calcium Channel Type L, Benzothiazepine radioligand binding (ligand: [3H] Diltiazem)",Confirmatory,,
399,625216,3,4,,103168637,6228,Unspecified,,,,IC50,"DRUGMATRIX: Calcium Channel Type L, Dihydropyridine radioligand binding (ligand: [3H] Nitrendipine)",Confirmatory,,
400,625217,4,7,,103168637,6228,Unspecified,1168220.0,3357.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2B radioligand binding (ligand: [3H] Lysergic acid diethylamide),Confirmatory,,
401,625218,4,7,,103168637,6228,Unspecified,112816.0,3358.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2C radioligand binding (ligand: [3H] Mesulergine),Confirmatory,,
402,625219,3,4,,103168637,6228,Unspecified,,,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT3 radioligand binding (ligand: [3H] GR-65630),Confirmatory,,
403,625220,4,7,,103168637,6228,Unspecified,6224984.0,100135548.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT4 radioligand binding (ligand: [3H] GR-113808),Confirmatory,,
404,625221,4,7,,103168637,6228,Unspecified,1703010.0,3362.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT6 radioligand binding (ligand: [3H] Lysergic acid diethylamide),Confirmatory,,
405,625222,4,7,,103168637,6228,Unspecified,400630.0,6532.0,,IC50,"DRUGMATRIX: Transporter, Serotonin (5-Hydroxytryptamine) (SERT) radioligand binding (ligand: [3H] Paroxetine)",Confirmatory,,
406,625223,4,7,,103168637,6228,Unspecified,74752153.0,10280.0,,IC50,DRUGMATRIX: Sigma1 radioligand binding (ligand: [3H] Haloperidol),Confirmatory,,
407,625224,3,4,,103168637,6228,Unspecified,,,,IC50,DRUGMATRIX: Sigma2 radioligand binding (ligand: [3H] Ifenprodil),Confirmatory,,
408,625225,3,4,,103168637,6228,Unspecified,,,,IC50,"DRUGMATRIX: Sodium Channel, Site 2 radioligand binding (ligand: [3H] Batrachotoxin)",Confirmatory,,
409,625226,4,7,,103168637,6228,Unspecified,128359.0,6869.0,,IC50,DRUGMATRIX: Tachykinin NK1 radioligand binding (ligand: [3H] Substance P),Confirmatory,,
410,625227,4,7,,103168637,6228,Unspecified,229462950.0,6865.0,,IC50,DRUGMATRIX: Tachykinin NK2 radioligand binding (ligand: [3H] SR-48968),Confirmatory,,
411,625228,4,7,,103168637,6228,Unspecified,113832.0,24208.0,,IC50,DRUGMATRIX: Androgen (Testosterone) AR radioligand binding (ligand: [3H] Mibolerone),Confirmatory,,
412,625229,5,5,,103168637,6228,Unspecified,254763392.0,6916.0,,IC50,DRUGMATRIX: Thromboxane Synthetase enzyme inhibition (substrate: PGH2),Confirmatory,,
413,625230,1,6,,103168637,6228,Unspecified,,,,,"DRUGMATRIX: Tumor Necrosis Factor (TNF), Non-Selective radioligand binding (ligand: [125I] TNF-alpha)",Other,,
414,625231,4,7,,103168637,6228,Unspecified,143811474.0,2321.0,,IC50,DRUGMATRIX: Vascular Endothelial Growth Factor (VEGF) radioligand binding (ligand: [125I] VEGF),Confirmatory,,
415,625232,1,9,,103168637,6228,Unspecified,418253.0,7433.0,,,DRUGMATRIX: Vasoactive Intestinal Peptide VIP1 radioligand binding (ligand: [125I] VIP),Other,,
416,625233,4,7,,103168637,6228,Unspecified,586197.0,552.0,,IC50,DRUGMATRIX: Vasopressin V1A radioligand binding (ligand: [125I] PhenylacetylTyr(Me)PheGlnAsnArgProArgTyr),Confirmatory,,
417,625234,3,4,,103168637,6228,Unspecified,,,,IC50,"DRUGMATRIX: Calcium Channel Type L, Phenylalkylamine radioligand binding (ligand: [3H] (-)-Desmethoxyverapamil (D-888))",Confirmatory,,
418,625235,4,7,,103168637,6228,Unspecified,115562.0,1268.0,,IC50,DRUGMATRIX: Cannabinoid CB1 radioligand binding (ligand: [3H] SR141716A),Confirmatory,,
419,625236,5,5,,103168637,6228,Unspecified,115456.0,760.0,,IC50,DRUGMATRIX: Carbonic Anhydrase II enzyme inhibition (substrate: 4-Nitrophenyl acetate (4-NPA)),Confirmatory,,
420,625237,4,7,,103168637,6228,Unspecified,1168965.0,729230.0,,IC50,DRUGMATRIX: Chemokine CCR2B radioligand binding (ligand: [125I] MCP-1),Confirmatory,,
421,625238,4,7,,103168637,6228,Unspecified,1705894.0,1233.0,,IC50,DRUGMATRIX: Chemokine CCR4 radioligand binding (ligand: [125I] TARC),Confirmatory,,
422,625239,4,7,,103168637,6228,Unspecified,1705896.0,1234.0,,IC50,DRUGMATRIX: Chemokine CCR5 radioligand binding (ligand: [125I] MIP-1alpha),Confirmatory,,
423,625240,1,9,,103168637,6228,Unspecified,108936015.0,3577.0,,,DRUGMATRIX: Chemokine CXCR1 (IL-8A),Other,,
424,625241,4,7,,103168637,6228,Unspecified,1352454.0,3579.0,,IC50,DRUGMATRIX: Chemokine CXCR2 (IL-8B) radioligand binding (ligand: [125I] IL-8),Confirmatory,,
425,625242,4,7,,103168637,6228,Unspecified,416772.0,886.0,,IC50,"DRUGMATRIX: Cholecystokinin CCKA radioligand binding (ligand: [3H] L-364,718)",Confirmatory,,
426,625243,5,5,,103168637,6228,Unspecified,317373262.0,5742.0,,IC50,DRUGMATRIX: Cyclooxygenase COX-1 enzyme inhibition (substrate: Arachidonic acid),Confirmatory,,
427,625244,5,5,,103168637,6228,Unspecified,3915797.0,5743.0,,IC50,DRUGMATRIX: Cyclooxygenase COX-2 enzyme inhibition (substrate: Arachidonic acid),Confirmatory,,
428,625245,5,5,,103168637,6228,Unspecified,117144.0,1544.0,,IC50,"DRUGMATRIX: CYP450, 1A2 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
429,625246,1,9,,103168637,6228,Unspecified,308153612.0,1548.0,,,"DRUGMATRIX: CYP450, 2A6 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Other,,
430,625247,5,5,,103168637,6228,Unspecified,60416369.0,1557.0,,IC50,"DRUGMATRIX: CYP450, 2C19 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
431,625248,5,5,,103168637,6228,Unspecified,6686268.0,1559.0,,IC50,"DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
432,625249,5,5,,103168637,6228,Unspecified,84028191.0,1565.0,,IC50,"DRUGMATRIX: CYP450, 2D6 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
433,625250,5,5,,103168637,6228,Unspecified,117250.0,1571.0,,IC50,"DRUGMATRIX: CYP450, 2E1 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
434,625251,5,5,,103168637,6228,Unspecified,116241312.0,1576.0,,IC50,"DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)",Confirmatory,,
435,625252,4,7,,103168637,6228,Unspecified,118228.0,1812.0,,IC50,DRUGMATRIX: Dopamine D1 radioligand binding (ligand: [3H] SCH-23390),Confirmatory,,
436,625253,4,7,,103168637,6228,Unspecified,118206.0,1813.0,,IC50,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
437,625254,4,7,,103168637,6228,Unspecified,1169206.0,1814.0,,IC50,DRUGMATRIX: Dopamine D3 radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
438,625255,4,7,,103168637,6228,Unspecified,1345939.0,1815.0,,IC50,DRUGMATRIX: Dopamine D4.2 radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
439,625256,4,7,,103168637,6228,Unspecified,266667.0,6531.0,,IC50,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),Confirmatory,,
440,625257,4,7,,103168637,6228,Unspecified,119606.0,1909.0,,IC50,DRUGMATRIX: Endothelin ETA radioligand binding (ligand: [125I] Endothelin-1),Confirmatory,,
441,625258,4,7,,103168637,6228,Unspecified,544257.0,2099.0,,IC50,DRUGMATRIX: Estrogen ERalpha radioligand binding (ligand: [3H] Estradiol),Confirmatory,,
442,625259,4,7,,103168637,6228,Unspecified,6166154.0,2100.0,,IC50,DRUGMATRIX: Estrogen ERbeta radioligand binding (ligand: [3H] Estradiol),Confirmatory,,
443,625260,3,4,,103168637,6228,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Muscimol, Central radioligand binding (ligand: [3H] Muscimol)",Confirmatory,,
444,625261,3,4,,103168637,6228,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Flunitrazepam, Central radioligand binding (ligand: [3H] Flunitrazepam)",Confirmatory,,
445,625262,3,4,,103168637,6228,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Chloride Channel, TBOB radioligand binding (ligand: [3H] TBOB)",Confirmatory,,
446,625263,4,7,,103168637,6228,Unspecified,121069.0,2908.0,,IC50,DRUGMATRIX: Glucocorticoid radioligand binding (ligand: [3H] Dexamethasone),Confirmatory,,
447,625264,3,4,,103168637,6228,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, AMPA radioligand binding (ligand: [3H] AMPA)",Confirmatory,,
448,625265,1,6,,103168637,6228,Unspecified,,,,,"DRUGMATRIX: Glutamate, Kainate radioligand binding (ligand: [3H] Kainic acid)",Other,,
449,625266,3,4,,103168637,6228,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, NMDA, Agonism radioligand binding (ligand: [3H] CGP-39653)",Confirmatory,,
450,625267,3,4,,103168637,6228,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, NMDA, Phencyclidine radioligand binding (ligand: [3H] TCP)",Confirmatory,,
451,625268,4,2,,103168637,6228,Unspecified,121579.0,24397.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
452,625268,4,2,,103168637,6228,Unspecified,121580.0,114516.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
453,625268,4,2,,103168637,6228,Unspecified,121604.0,25456.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
454,625268,4,2,,103168637,6228,Unspecified,12230887.0,25674.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
455,625269,4,7,,103168637,6228,Unspecified,547645.0,3269.0,,IC50,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",Confirmatory,,
456,625270,4,7,,103168637,6228,Unspecified,123120.0,3274.0,,IC50,DRUGMATRIX: Histamine H2 radioligand binding (ligand: [125I] Aminopotentidine),Confirmatory,,
457,625271,5,5,,103168637,6228,Unspecified,123343.0,3156.0,,IC50,DRUGMATRIX: HMG-CoA Reductase enzyme inhibition (substrate: [14C]HMG-CoA),Confirmatory,,
458,625272,3,4,,103168637,6228,Unspecified,,,,IC50,"DRUGMATRIX: Imidazoline I2, Central radioligand binding (ligand: [3H] Idazoxan)",Confirmatory,,
459,625273,4,6,,103168637,6228,Unspecified,124531.0,24954.0,,IC50,DRUGMATRIX: Insulin radioligand binding (ligand: [125I] Insulin),Confirmatory,,
460,625274,1,6,,103168637,6228,Unspecified,,,,,DRUGMATRIX: Interleukin IL-1 radioligand binding (ligand: [125I] interleukin 1beta),Other,,
461,625275,3,4,,103168637,6228,Unspecified,,,,IC50,"DRUGMATRIX: Leukotriene, BLT (LTB4) radioligand binding (ligand: [3H]LTB4)",Confirmatory,,
462,651631,4,1,,144208457,6228,Inconclusive,269849759.0,7157.0,,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway,Confirmatory,,
463,651631,4,1,,144210359,6228,Inactive,269849759.0,7157.0,,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway,Confirmatory,,
464,651632,4,1,,144208457,6228,Inactive,296439460.0,79915.0,,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5,Confirmatory,,
465,651632,4,1,,144210359,6228,Inactive,296439460.0,79915.0,,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5,Confirmatory,,
466,651633,4,1,,144208457,6228,Inactive,,,0.557,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway - cell viability,Confirmatory,,
467,651633,4,1,,144210359,6228,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway - cell viability,Confirmatory,,
468,651634,4,1,,144208457,6228,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5 - cell viability,Confirmatory,,
469,651634,4,1,,144210359,6228,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5 - cell viability,Confirmatory,,
470,651741,1,1,,17388882,6228,Inconclusive,20149576.0,4780.0,,Potency,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway,Confirmatory,,
471,651741,1,1,,17389908,6228,Inactive,20149576.0,4780.0,,Potency,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway,Confirmatory,,
472,651741,1,1,,26752801,6228,Inconclusive,20149576.0,4780.0,,Potency,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway,Confirmatory,,
473,651743,1,1,,17388882,6228,Inactive,269849759.0,7157.0,,Potency,qHTS assay for small molecule activators of the p53 signaling pathway,Confirmatory,,
474,651743,1,1,,17389908,6228,Inactive,269849759.0,7157.0,,Potency,qHTS assay for small molecule activators of the p53 signaling pathway,Confirmatory,,
475,651743,1,1,,26752801,6228,Inactive,269849759.0,7157.0,,Potency,qHTS assay for small molecule activators of the p53 signaling pathway,Confirmatory,,
476,651749,1,1,,17388882,6228,Inactive,34577122.0,4790.0,,Potency,qHTS assay for small molecule activators of the nuclear factor-kappa B (NF-kB) signaling pathway,Confirmatory,,
477,651749,1,1,,17389908,6228,Inactive,34577122.0,4790.0,,Potency,qHTS assay for small molecule activators of the nuclear factor-kappa B (NF-kB) signaling pathway,Confirmatory,,
478,651749,1,1,,26752801,6228,Inactive,34577122.0,4790.0,,Potency,qHTS assay for small molecule activators of the nuclear factor-kappa B (NF-kB) signaling pathway,Confirmatory,,
479,651751,1,1,,17388882,6228,Inactive,5702233.0,84385.0,,Potency,qHTS assay for small molecule activators of the rat pregnane X receptor (rPXR) signaling pathway,Confirmatory,,
480,651751,1,1,,17389908,6228,Inactive,5702233.0,84385.0,,Potency,qHTS assay for small molecule activators of the rat pregnane X receptor (rPXR) signaling pathway,Confirmatory,,
481,651751,1,1,,26752801,6228,Inactive,5702233.0,84385.0,,Potency,qHTS assay for small molecule activators of the rat pregnane X receptor (rPXR) signaling pathway,Confirmatory,,
482,651754,1,1,,17388882,6228,Inactive,,,,Potency,qHTS assay for small molecule disruptors of the mitochondrial membrane potential - 1 hr assay,Confirmatory,,
483,651754,1,1,,17389908,6228,Inconclusive,,,,Potency,qHTS assay for small molecule disruptors of the mitochondrial membrane potential - 1 hr assay,Confirmatory,,
484,651755,1,1,,17388882,6228,Inactive,,,,Potency,qHTS assay for small molecule disruptors of the mitochondrial membrane potential - 5 hr assay,Confirmatory,,
485,651755,1,1,,17389908,6228,Inactive,,,,Potency,qHTS assay for small molecule disruptors of the mitochondrial membrane potential - 5 hr assay,Confirmatory,,
486,651757,1,1,,17388882,6228,Inactive,25952111.0,7124.0,,Potency,qHTS assay to identify small molecules that stimulate Tumor Necrosis Factor-alpha (TNF-alpha) secretion,Confirmatory,,
487,651757,1,1,,17389908,6228,Inactive,25952111.0,7124.0,,Potency,qHTS assay to identify small molecules that stimulate Tumor Necrosis Factor-alpha (TNF-alpha) secretion,Confirmatory,,
488,651758,1,1,,17388882,6228,Inconclusive,186368.0,3576.0,,Potency,qHTS assay to identify small molecules that stimulate interleukin-8 (IL-8) secretion,Confirmatory,,
489,651758,1,1,,17389908,6228,Inactive,186368.0,3576.0,,Potency,qHTS assay to identify small molecules that stimulate interleukin-8 (IL-8) secretion,Confirmatory,,
490,651777,1,1,,17388882,6228,Inactive,51095037.0,196.0,,Potency,qHTS assay for environmental chemicals that activate the Aryl hydrocarbon Receptor (AhR) signaling pathway,Confirmatory,,
491,651777,1,1,,17389908,6228,Inactive,51095037.0,196.0,,Potency,qHTS assay for environmental chemicals that activate the Aryl hydrocarbon Receptor (AhR) signaling pathway,Confirmatory,,
492,651777,1,1,,26752801,6228,Inactive,51095037.0,196.0,,Potency,qHTS assay for environmental chemicals that activate the Aryl hydrocarbon Receptor (AhR) signaling pathway,Confirmatory,,
493,651778,1,1,,17388882,6228,Inactive,3041727.0,5465.0,,Potency,qHTS assay for small molecule agonists of the peroxisome proliferator-activated receptor alpha (PPARalpha) signaling pathway,Confirmatory,,
494,651778,1,1,,17389908,6228,Inactive,3041727.0,5465.0,,Potency,qHTS assay for small molecule agonists of the peroxisome proliferator-activated receptor alpha (PPARalpha) signaling pathway,Confirmatory,,
495,651778,1,1,,26752801,6228,Inactive,3041727.0,5465.0,,Potency,qHTS assay for small molecule agonists of the peroxisome proliferator-activated receptor alpha (PPARalpha) signaling pathway,Confirmatory,,
496,651802,1,1,,17388882,6228,Inactive,49066040.0,6097.0,,Potency,qHTS assay for small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway,Confirmatory,,
497,651802,1,1,,17389908,6228,Inactive,49066040.0,6097.0,,Potency,qHTS assay for small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway,Confirmatory,,
498,651838,1,1,,17388882,6228,Unspecified,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
499,651838,1,1,,17389908,6228,Unspecified,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
500,651838,1,1,,26752801,6228,Unspecified,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
501,651838,1,1,1.0,17388882,6228,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
502,651838,1,1,1.0,17389908,6228,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
503,651838,1,1,1.0,26752801,6228,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
504,651838,1,1,2.0,17388882,6228,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
505,651838,1,1,2.0,17389908,6228,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
506,651838,1,1,2.0,26752801,6228,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
507,651838,1,1,3.0,17388882,6228,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
508,651838,1,1,3.0,17389908,6228,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
509,651838,1,1,3.0,26752801,6228,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
510,651838,1,1,4.0,17388882,6228,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
511,651838,1,1,4.0,17389908,6228,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
512,651838,1,1,4.0,26752801,6228,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
513,651838,1,1,5.0,17388882,6228,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
514,651838,1,1,5.0,17389908,6228,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
515,651838,1,1,5.0,26752801,6228,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
516,651838,1,1,6.0,17388882,6228,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
517,651838,1,1,6.0,17389908,6228,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
518,651838,1,1,6.0,26752801,6228,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
519,651838,1,1,7.0,17388882,6228,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
520,651838,1,1,7.0,17389908,6228,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
521,651838,1,1,7.0,26752801,6228,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
522,651838,1,1,8.0,17388882,6228,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
523,651838,1,1,8.0,17389908,6228,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
524,651838,1,1,8.0,26752801,6228,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
525,720516,2,1,,144208457,6228,Inactive,296439460.0,79915.0,,ATAD5 Potency (uM),qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5: Summary,Summary,,
526,720516,2,1,,144210359,6228,Inactive,296439460.0,79915.0,,ATAD5 Potency (uM),qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5: Summary,Summary,,
527,720552,2,1,,144208457,6228,Inactive,269849759.0,7157.0,,Ratio Potency (uM),qHTS assay for small molecule agonists of the p53 signaling pathway: Summary,Summary,,
528,720552,2,1,,144210359,6228,Inactive,269849759.0,7157.0,,Ratio Potency (uM),qHTS assay for small molecule agonists of the p53 signaling pathway: Summary,Summary,,
529,720634,2,1,,144208457,6228,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential - cell viability,Confirmatory,,
530,720634,2,1,,144210359,6228,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential - cell viability,Confirmatory,,
531,720635,2,1,,144208457,6228,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential,Confirmatory,,
532,720635,2,1,,144210359,6228,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential,Confirmatory,,
533,720636,1,1,,17388882,6228,Inactive,20149576.0,4780.0,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway measured by Nrf2-dependant transcriptional activity,Confirmatory,,
534,720636,1,1,,17389908,6228,Inactive,20149576.0,4780.0,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway measured by Nrf2-dependant transcriptional activity,Confirmatory,,
535,720636,1,1,,26752801,6228,Inactive,20149576.0,4780.0,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway measured by Nrf2-dependant transcriptional activity,Confirmatory,,
536,720637,2,1,,144208457,6228,Inactive,,,,Ratio Potency (uM),qHTS assay for small molecule disruptors of the mitochondrial membrane potential: Summary,Summary,,
537,720637,2,1,,144210359,6228,Inactive,,,,Ratio Potency (uM),qHTS assay for small molecule disruptors of the mitochondrial membrane potential: Summary,Summary,,
538,720652,1,1,,17388882,6228,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway - cell viability counter screen,Confirmatory,,
539,720652,1,1,,17389908,6228,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway - cell viability counter screen,Confirmatory,,
540,720653,1,1,,17388882,6228,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway measured by Nrf2-dependant transcriptional activity - cell viability counter screen,Confirmatory,,
541,720653,1,1,,17389908,6228,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway measured by Nrf2-dependant transcriptional activity - cell viability counter screen,Confirmatory,,
542,720653,1,1,,26752801,6228,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway measured by Nrf2-dependant transcriptional activity - cell viability counter screen,Confirmatory,,
543,720659,1,1,,17388882,6228,Inactive,325495557.0,8856.0,,Potency-Replicate_1,qHTS assay for small molecule activators of the human pregnane X receptor (PXR) signaling pathway,Confirmatory,,
544,720659,1,1,,17389908,6228,Inactive,325495557.0,8856.0,,Potency-Replicate_1,qHTS assay for small molecule activators of the human pregnane X receptor (PXR) signaling pathway,Confirmatory,,
545,720659,1,1,,26752801,6228,Inactive,325495557.0,8856.0,,Potency-Replicate_1,qHTS assay for small molecule activators of the human pregnane X receptor (PXR) signaling pathway,Confirmatory,,
546,720674,2,2,,144208457,6228,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cells,Confirmatory,,
547,720674,2,2,,144210359,6228,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cells,Confirmatory,,
548,720675,2,2,,144208457,6228,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cells,Confirmatory,,
549,720675,2,2,,144210359,6228,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cells,Confirmatory,,
550,720678,2,1,,144208457,6228,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cells,Confirmatory,,
551,720678,2,1,,144210359,6228,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cells,Confirmatory,,
552,720679,2,1,,144208457,6228,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cells,Confirmatory,,
553,720679,2,1,,144210359,6228,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cells,Confirmatory,,
554,720680,2,1,,144208457,6228,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cells,Confirmatory,,
555,720680,2,1,,144210359,6228,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cells,Confirmatory,,
556,720681,2,1,,144208457,6228,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cell free culture,Confirmatory,,
557,720681,2,1,,144210359,6228,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cell free culture,Confirmatory,,
558,720682,2,1,,144208457,6228,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cell free culture,Confirmatory,,
559,720682,2,1,,144210359,6228,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cell free culture,Confirmatory,,
560,720683,2,1,,144208457,6228,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cell free culture,Confirmatory,,
561,720683,2,1,,144210359,6228,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cell free culture,Confirmatory,,
562,720684,2,1,,144208457,6228,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cell free culture,Confirmatory,,
563,720684,2,1,,144210359,6228,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cell free culture,Confirmatory,,
564,720685,2,1,,144208457,6228,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cell free culture,Confirmatory,,
565,720685,2,1,,144210359,6228,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cell free culture,Confirmatory,,
566,720686,2,1,,144208457,6228,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cell free culture,Confirmatory,,
567,720686,2,1,,144210359,6228,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cell free culture,Confirmatory,,
568,720687,2,2,,144208457,6228,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cells,Confirmatory,,
569,720687,2,2,,144210359,6228,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cells,Confirmatory,,
570,720691,4,1,,144208457,6228,Inactive,311348376.0,2908.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
571,720691,4,1,,144210359,6228,Inactive,311348376.0,2908.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
572,720692,3,1,,144208457,6228,Inactive,311348376.0,2908.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
573,720692,3,1,,144210359,6228,Inactive,311348376.0,2908.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
574,720693,3,1,,144208457,6228,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway - cell viability counter screen,Confirmatory,,
575,720693,3,1,,144210359,6228,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway - cell viability counter screen,Confirmatory,,
576,720719,2,1,,144208457,6228,Inactive,311348376.0,2908.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
577,720719,2,1,,144210359,6228,Inactive,311348376.0,2908.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
578,720725,2,1,,144208457,6228,Inactive,311348376.0,2908.0,,,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
579,720725,2,1,,144210359,6228,Inactive,311348376.0,2908.0,,,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
580,743012,3,1,,144208457,6228,Inactive,,,,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - wild type cell line,Confirmatory,,
581,743012,3,1,,144210359,6228,Inactive,,,,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - wild type cell line,Confirmatory,,
582,743014,3,1,,144208457,6228,Inactive,,,,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rev3 mutant cell line,Confirmatory,,
583,743014,3,1,,144210359,6228,Inactive,,,,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rev3 mutant cell line,Confirmatory,,
584,743015,3,1,,144208457,6228,Inactive,,,,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rad54/Ku70 mutant cell line,Confirmatory,,
585,743015,3,1,,144210359,6228,Inactive,,,,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rad54/Ku70 mutant cell line,Confirmatory,,
586,743033,3,1,,144208457,6228,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway - cell viability counter screen,Confirmatory,,
587,743033,3,1,,144210359,6228,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway - cell viability counter screen,Confirmatory,,
588,743035,2,1,,144208457,6228,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
589,743035,2,1,,144210359,6228,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
590,743036,2,1,,144208457,6228,Inconclusive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
591,743036,2,1,,144210359,6228,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
592,743040,3,1,,144208457,6228,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
593,743040,3,1,,144210359,6228,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
594,743041,3,1,,144208457,6228,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line - cell viability counter screen,Confirmatory,,
595,743041,3,1,,144210359,6228,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line - cell viability counter screen,Confirmatory,,
596,743042,3,1,,144208457,6228,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
597,743042,3,1,,144210359,6228,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
598,743053,2,1,,144208457,6228,Inactive,124375976.0,367.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
599,743053,2,1,,144210359,6228,Inactive,124375976.0,367.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
600,743054,2,1,,144208457,6228,Inactive,124375976.0,367.0,,AR Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line: Summary,Summary,,
601,743054,2,1,,144210359,6228,Inactive,124375976.0,367.0,,AR Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line: Summary,Summary,,
602,743063,2,1,,144208457,6228,Inactive,124375976.0,367.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
603,743063,2,1,,144210359,6228,Inactive,124375976.0,367.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
604,743064,3,1,,144208457,6228,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway - cell viability counter screen,Confirmatory,,
605,743064,3,1,,144210359,6228,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway - cell viability counter screen,Confirmatory,,
606,743065,3,1,,144208457,6228,Inactive,399498506.0,24831.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
607,743065,3,1,,144210359,6228,Inactive,399498506.0,24831.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
608,743066,3,1,,144208457,6228,Inactive,399498506.0,24831.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
609,743066,3,1,,144210359,6228,Inactive,399498506.0,24831.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
610,743067,2,1,,144208457,6228,Inconclusive,399498506.0,24831.0,,TR Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway: Summary,Summary,,
611,743067,2,1,,144210359,6228,Inactive,399498506.0,24831.0,,TR Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway: Summary,Summary,,
612,743069,2,1,,144208457,6228,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
613,743069,2,1,,144210359,6228,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
614,743074,2,1,,144208457,6228,Inconclusive,,,19.9287,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway - cell viability counter screen,Confirmatory,,
615,743074,2,1,,144210359,6228,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway - cell viability counter screen,Confirmatory,,
616,743075,2,1,,144208457,6228,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
617,743075,2,1,,144210359,6228,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
618,743077,2,1,,144208457,6228,Inactive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
619,743077,2,1,,144210359,6228,Inactive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
620,743078,2,1,,144208457,6228,Inactive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
621,743078,2,1,,144210359,6228,Inactive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
622,743079,3,1,,144208457,6228,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
623,743079,3,1,,144210359,6228,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
624,743080,3,1,,144208457,6228,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
625,743080,3,1,,144210359,6228,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
626,743081,3,1,,144208457,6228,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line - cell viability counter screen,Confirmatory,,
627,743081,3,1,,144210359,6228,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line - cell viability counter screen,Confirmatory,,
628,743083,3,1,,144208457,6228,Inactive,119597822.0,1588.0,,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors,Confirmatory,,
629,743083,3,1,,144210359,6228,Inactive,119597822.0,1588.0,,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors,Confirmatory,,
630,743084,3,1,,144208457,6228,Inactive,,,,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors - cell viability counter screen,Confirmatory,,
631,743084,3,1,,144210359,6228,Inactive,,,,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors - cell viability counter screen,Confirmatory,,
632,743085,3,1,,144208457,6228,Inactive,51095037.0,196.0,,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway,Confirmatory,,
633,743085,3,1,,144210359,6228,Inactive,51095037.0,196.0,,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway,Confirmatory,,
634,743086,3,1,,144208457,6228,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway - cell viability counter screen,Confirmatory,,
635,743086,3,1,,144210359,6228,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway - cell viability counter screen,Confirmatory,,
636,743091,2,1,,144208457,6228,Inactive,348019627.0,2099.0,,ER Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line: Summary,Summary,,
637,743091,2,1,,144210359,6228,Inactive,348019627.0,2099.0,,ER Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line: Summary,Summary,,
638,743094,3,1,,144208457,6228,Inactive,216409692.0,5468.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
639,743094,3,1,,144210359,6228,Inactive,216409692.0,5468.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
640,743122,2,1,,144208457,6228,Inactive,51095037.0,196.0,,AhR Potency (uM),qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway: Summary,Summary,,
641,743122,2,1,,144210359,6228,Inactive,51095037.0,196.0,,AhR Potency (uM),qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway: Summary,Summary,,
642,743139,2,1,,144208457,6228,Inactive,119597822.0,1588.0,,,qHTS assay to identify aromatase inhibitors: Summary,Summary,,
643,743139,2,1,,144210359,6228,Inactive,119597822.0,1588.0,,,qHTS assay to identify aromatase inhibitors: Summary,Summary,,
644,743140,2,1,,144208457,6228,Inactive,216409692.0,5468.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
645,743140,2,1,,144210359,6228,Inactive,216409692.0,5468.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
646,743191,3,1,,144208457,6228,Inactive,216409692.0,5468.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
647,743191,3,1,,144210359,6228,Inconclusive,216409692.0,5468.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
648,743194,3,1,,144208457,6228,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway - cell viability counter screen,Confirmatory,,
649,743194,3,1,,144210359,6228,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway - cell viability counter screen,Confirmatory,,
650,743199,2,1,,144208457,6228,Inactive,216409692.0,5468.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
651,743199,2,1,,144210359,6228,Inactive,216409692.0,5468.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
652,743202,4,1,,144208457,6228,Inactive,20149576.0,4780.0,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway,Confirmatory,,
653,743202,4,1,,144210359,6228,Inactive,20149576.0,4780.0,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway,Confirmatory,,
654,743203,3,1,,144208457,6228,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway - cell viability counter screen,Confirmatory,,
655,743203,3,1,,144210359,6228,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway - cell viability counter screen,Confirmatory,,
656,743209,3,1,,144208457,6228,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway - cell viability counter screen,Confirmatory,,
657,743209,3,1,,144210359,6228,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway - cell viability counter screen,Confirmatory,,
658,743210,4,1,,144208457,6228,Inactive,4504517.0,3315.0,,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway,Confirmatory,,
659,743210,4,1,,144210359,6228,Inactive,4504517.0,3315.0,,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway,Confirmatory,,
660,743211,3,1,,144208457,6228,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
661,743211,3,1,,144210359,6228,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
662,743212,3,1,,144208457,6228,Inactive,216409690.0,5467.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
663,743212,3,1,,144210359,6228,Inactive,216409690.0,5467.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
664,743213,3,1,,144208457,6228,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
665,743213,3,1,,144210359,6228,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
666,743215,3,1,,144208457,6228,Inactive,216409690.0,5467.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
667,743215,3,1,,144210359,6228,Inactive,216409690.0,5467.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
668,743217,3,1,,144208457,6228,Inactive,325495553.0,9971.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
669,743217,3,1,,144210359,6228,Inactive,325495553.0,9971.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
670,743218,3,1,,144208457,6228,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
671,743218,3,1,,144210359,6228,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
672,743219,3,1,,144208457,6228,Inactive,20149576.0,4780.0,,Ratio Potency (uM),qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway: Summary,Summary,,
673,743219,3,1,,144210359,6228,Inactive,20149576.0,4780.0,,Ratio Potency (uM),qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway: Summary,Summary,,
674,743220,3,1,,144208457,6228,Inactive,325495553.0,9971.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
675,743220,3,1,,144210359,6228,Inactive,325495553.0,9971.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
676,743221,3,1,,144208457,6228,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
677,743221,3,1,,144210359,6228,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
678,743222,3,1,,144208457,6228,Inactive,216409708.0,7421.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
679,743222,3,1,,144210359,6228,Inactive,216409708.0,7421.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
680,743223,3,1,,144208457,6228,Inactive,216409708.0,7421.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
681,743223,3,1,,144210359,6228,Inactive,216409708.0,7421.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
682,743224,3,1,,144208457,6228,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
683,743224,3,1,,144210359,6228,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
684,743225,3,1,,144208457,6228,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
685,743225,3,1,,144210359,6228,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
686,743226,2,1,,144208457,6228,Inactive,216409690.0,5467.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
687,743226,2,1,,144210359,6228,Inactive,216409690.0,5467.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
688,743227,2,1,,144208457,6228,Inactive,216409690.0,5467.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
689,743227,2,1,,144210359,6228,Inactive,216409690.0,5467.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
690,743228,3,1,,144208457,6228,Inactive,4504517.0,3315.0,,Ratio Potency (uM),qHTS assay for small molecule activators of the heat shock response signaling pathway: Summary,Summary,,
691,743228,3,1,,144210359,6228,Inactive,4504517.0,3315.0,,Ratio Potency (uM),qHTS assay for small molecule activators of the heat shock response signaling pathway: Summary,Summary,,
692,743239,2,1,,144208457,6228,Inactive,325495553.0,9971.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
693,743239,2,1,,144210359,6228,Inactive,325495553.0,9971.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
694,743240,2,1,,144208457,6228,Inactive,325495553.0,9971.0,,,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
695,743240,2,1,,144210359,6228,Inactive,325495553.0,9971.0,,,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
696,743241,2,1,,144208457,6228,Inactive,216409708.0,7421.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
697,743241,2,1,,144210359,6228,Inactive,216409708.0,7421.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
698,743242,2,1,,144208457,6228,Inactive,216409708.0,7421.0,,,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
699,743242,2,1,,144210359,6228,Inactive,216409708.0,7421.0,,,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
700,743288,1,1,,17388882,6228,Inactive,,,,Potency,qHTS assay for cell viability of HEK293 cells,Confirmatory,,
701,743288,1,1,,17389908,6228,Inactive,,,,Potency,qHTS assay for cell viability of HEK293 cells,Confirmatory,,
702,743288,1,1,,26752801,6228,Inactive,,,,Potency,qHTS assay for cell viability of HEK293 cells,Confirmatory,,
703,743292,1,1,,17388882,6228,Inactive,,,,Potency,qHTS assay for cell viability of the p53RE-bla HCT-116 cell line,Confirmatory,,
704,743292,1,1,,17389908,6228,Inactive,,,,Potency,qHTS assay for cell viability of the p53RE-bla HCT-116 cell line,Confirmatory,,
705,743292,1,1,,26752801,6228,Inactive,,,,Potency,qHTS assay for cell viability of the p53RE-bla HCT-116 cell line,Confirmatory,,
706,922448,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: BASO (Basophils); Study_ID: I011106,Other,,
707,922449,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: I011106,Other,,
708,922450,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: I011106,Other,,
709,922451,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: I011106,Other,,
710,922452,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: NEUTSG (Neutrophils, Segmented); Study_ID: I011106",Other,,
711,922453,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: EOS (Eosinophils); Study_ID: I011106,Other,,
712,922454,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: RBCNUC (Nucleated Erythrocytes); Study_ID: I011106,Other,,
713,922455,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: LYM (Lymphocytes); Study_ID: I011106,Other,,
714,922456,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: I011106,Other,,
715,922457,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: I011106,Other,,
716,922458,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: I011106,Other,,
717,922459,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: I011106,Other,,
718,922460,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: I011106,Other,,
719,922461,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: I011106,Other,,
720,922462,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: I011106,Other,,
721,922463,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: MONO (Monocytes); Study_ID: I011106,Other,,
722,922464,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: I011106,Other,,
723,922465,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: I011106,Other,,
724,922466,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: I011106,Other,,
725,922467,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: BASO (Basophils); Study_ID: S010924,Other,,
726,922468,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: S010924,Other,,
727,922469,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: S010924,Other,,
728,922470,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: EOS (Eosinophils); Study_ID: S010924,Other,,
729,922471,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: S010924,Other,,
730,922472,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: S010924,Other,,
731,922473,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: RBCNUC (Nucleated Erythrocytes); Study_ID: S010924,Other,,
732,922474,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: S010924,Other,,
733,922475,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: LYM (Lymphocytes); Study_ID: S010924,Other,,
734,922476,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: NEUTSG (Neutrophils, Segmented); Study_ID: S010924",Other,,
735,922477,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: S010924,Other,,
736,922478,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: S010924,Other,,
737,925410,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: I011106,Other,,
738,925411,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: EOS (Eosinophils); Study_ID: I011106,Other,,
739,925412,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: I011106,Other,,
740,925413,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: I011106,Other,,
741,925414,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: RBCNUC (Nucleated Erythrocytes); Study_ID: I011106,Other,,
742,925415,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: I011106,Other,,
743,925416,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: I011106,Other,,
744,925417,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: I011106,Other,,
745,927429,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: I011106,Other,,
746,927430,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: I011106,Other,,
747,927431,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: LYM (Lymphocytes); Study_ID: I011106,Other,,
748,927432,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: NEUTSG (Neutrophils, Segmented); Study_ID: I011106",Other,,
749,927433,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: I011106,Other,,
750,927434,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: MONO (Monocytes); Study_ID: I011106,Other,,
751,927435,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: I011106,Other,,
752,927436,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: I011106,Other,,
753,927437,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: I011106,Other,,
754,927438,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: BASO (Basophils); Study_ID: S010924,Other,,
755,927439,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: LYM (Lymphocytes); Study_ID: S010924,Other,,
756,927440,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: S010924,Other,,
757,927441,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: S010924,Other,,
758,927442,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: S010924,Other,,
759,927443,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: S010924,Other,,
760,927444,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: EOS (Eosinophils); Study_ID: S010924,Other,,
761,927445,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: RBCNUC (Nucleated Erythrocytes); Study_ID: S010924,Other,,
762,927446,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: S010924,Other,,
763,927447,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: S010924,Other,,
764,927448,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: S010924,Other,,
765,927449,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: MONO (Monocytes); Study_ID: S010924,Other,,
766,927450,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: S010924,Other,,
767,927451,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: S010924,Other,,
768,927452,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: S010924,Other,,
769,927453,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: NEUTSG (Neutrophils, Segmented); Study_ID: S010924",Other,,
770,927454,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: S010924,Other,,
771,927455,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: S010924,Other,,
772,928085,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: S010924,Other,,
773,928086,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: BASO (Basophils); Study_ID: I011106,Other,,
774,928087,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: I011106,Other,,
775,928088,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: NEUTSG (Neutrophils, Segmented); Study_ID: I011106",Other,,
776,928089,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: I011106,Other,,
777,928090,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: I011106,Other,,
778,928091,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: I011106,Other,,
779,928092,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: EOS (Eosinophils); Study_ID: I011106,Other,,
780,928093,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: I011106,Other,,
781,928094,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: RBCNUC (Nucleated Erythrocytes); Study_ID: I011106,Other,,
782,928095,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: I011106,Other,,
783,928096,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: I011106,Other,,
784,928097,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: I011106,Other,,
785,928098,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: LYM (Lymphocytes); Study_ID: I011106,Other,,
786,928099,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: I011106,Other,,
787,928100,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: I011106,Other,,
788,928101,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: MONO (Monocytes); Study_ID: I011106,Other,,
789,930115,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: I011106,Other,,
790,930116,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: I011106,Other,,
791,930117,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: I011106,Other,,
792,932729,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: BASO (Basophils); Study_ID: S010924,Other,,
793,932730,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: S010924,Other,,
794,932731,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: NEUTSG (Neutrophils, Segmented); Study_ID: S010924",Other,,
795,932732,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: S010924,Other,,
796,932733,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: S010924,Other,,
797,932734,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: S010924,Other,,
798,932735,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: EOS (Eosinophils); Study_ID: S010924,Other,,
799,932736,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: S010924,Other,,
800,932737,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: S010924,Other,,
801,932738,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: S010924,Other,,
802,932739,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: RBCNUC (Nucleated Erythrocytes); Study_ID: S010924,Other,,
803,932740,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: S010924,Other,,
804,932741,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: S010924,Other,,
805,932742,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: S010924,Other,,
806,932743,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: LYM (Lymphocytes); Study_ID: S010924,Other,,
807,932744,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: MONO (Monocytes); Study_ID: S010924,Other,,
808,932745,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: S010924,Other,,
809,932746,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: S010924,Other,,
810,932747,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: S010924,Other,,
811,932748,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: BASO (Basophils); Study_ID: I011106,Other,,
812,932749,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: I011106,Other,,
813,932750,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: I011106,Other,,
814,932751,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: I011106,Other,,
815,932752,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: I011106,Other,,
816,932753,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: EOS (Eosinophils); Study_ID: I011106,Other,,
817,932754,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: RBCNUC (Nucleated Erythrocytes); Study_ID: I011106,Other,,
818,932755,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: LYM (Lymphocytes); Study_ID: I011106,Other,,
819,932756,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: NEUTSG (Neutrophils, Segmented); Study_ID: I011106",Other,,
820,932757,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: I011106,Other,,
821,932758,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: I011106,Other,,
822,932759,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: I011106,Other,,
823,932760,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: I011106,Other,,
824,932761,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: I011106,Other,,
825,932762,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: I011106,Other,,
826,932763,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: MONO (Monocytes); Study_ID: I011106,Other,,
827,932764,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: I011106,Other,,
828,932765,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: I011106,Other,,
829,932766,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: I011106,Other,,
830,932767,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: BASO (Basophils); Study_ID: S010924,Other,,
831,932768,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: S010924,Other,,
832,932769,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: S010924,Other,,
833,935413,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: NEUTSG (Neutrophils, Segmented); Study_ID: S010924",Other,,
834,935414,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: S010924,Other,,
835,935415,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: S010924,Other,,
836,935416,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: S010924,Other,,
837,935417,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: EOS (Eosinophils); Study_ID: S010924,Other,,
838,935418,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: S010924,Other,,
839,935419,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: RBCNUC (Nucleated Erythrocytes); Study_ID: S010924,Other,,
840,935420,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: S010924,Other,,
841,935421,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: LYM (Lymphocytes); Study_ID: S010924,Other,,
842,935422,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: S010924,Other,,
843,935423,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: S010924,Other,,
844,935424,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: S010924,Other,,
845,935425,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: S010924,Other,,
846,935426,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: MONO (Monocytes); Study_ID: S010924,Other,,
847,935427,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: S010924,Other,,
848,935428,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: S010924,Other,,
849,935429,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: BASO (Basophils); Study_ID: S010924,Other,,
850,935430,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: S010924,Other,,
851,935431,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: EOS (Eosinophils); Study_ID: S010924,Other,,
852,935432,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: NEUTSG (Neutrophils, Segmented); Study_ID: S010924",Other,,
853,935433,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: S010924,Other,,
854,935434,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: S010924,Other,,
855,935435,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: RBCNUC (Nucleated Erythrocytes); Study_ID: S010924,Other,,
856,935436,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: S010924,Other,,
857,935437,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: S010924,Other,,
858,935438,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: LYM (Lymphocytes); Study_ID: S010924,Other,,
859,935439,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: MONO (Monocytes); Study_ID: S010924,Other,,
860,935440,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: S010924,Other,,
861,935441,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: S010924,Other,,
862,935442,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: S010924,Other,,
863,935443,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: S010924,Other,,
864,935444,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: S010924,Other,,
865,935445,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: S010924,Other,,
866,935446,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: S010924,Other,,
867,935447,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: S010924,Other,,
868,935448,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: BASO (Basophils); Study_ID: I011106,Other,,
869,935449,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: I011106,Other,,
870,941865,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: S010924,Other,,
871,941866,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: MONO (Monocytes); Study_ID: S010924,Other,,
872,942495,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: S010924,Other,,
873,942496,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: S010924,Other,,
874,942497,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: S010924,Other,,
875,942498,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: S010924,Other,,
876,942499,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: S010924,Other,,
877,942500,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 7 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: BASO (Basophils); Study_ID: S010924,Other,,
878,942501,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 7 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: MONO (Monocytes); Study_ID: S010924,Other,,
879,942502,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 7 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: S010924,Other,,
880,942503,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 7 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: NEUTSG (Neutrophils, Segmented); Study_ID: S010924",Other,,
881,942504,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 7 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: S010924,Other,,
882,942505,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 7 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: EOS (Eosinophils); Study_ID: S010924,Other,,
883,942506,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 7 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: S010924,Other,,
884,942507,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 7 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: RBCNUC (Nucleated Erythrocytes); Study_ID: S010924,Other,,
885,942508,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 7 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: LYM (Lymphocytes); Study_ID: S010924,Other,,
886,942509,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 7 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: S010924,Other,,
887,942510,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 7 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: S010924,Other,,
888,942511,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 7 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: S010924,Other,,
889,942512,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 7 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: S010924,Other,,
890,942513,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 7 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: S010924,Other,,
891,942514,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 7 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: S010924,Other,,
892,942515,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 7 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: S010924,Other,,
893,942516,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 7 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: S010924,Other,,
894,942517,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 7 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: S010924,Other,,
895,942518,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 7 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: S010924,Other,,
896,956137,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: I011106,Other,,
897,956138,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: I011106,Other,,
898,956139,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: I011106,Other,,
899,956140,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: I011106,Other,,
900,956141,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: I011106,Other,,
901,956708,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: I011106,Other,,
902,956709,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: I011106,Other,,
903,956710,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: CK (Creatine Kinase); Study_ID: I011106,Other,,
904,956711,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: I011106,Other,,
905,956712,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: I011106,Other,,
906,956713,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: CO2 (Carbon Dioxide); Study_ID: I011106,Other,,
907,956714,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: I011106,Other,,
908,956715,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: I011106,Other,,
909,956716,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: I011106,Other,,
910,956717,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: LIPASE (Triacylglycerol Lipase); Study_ID: I011106,Other,,
911,956718,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: I011106,Other,,
912,958602,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: URATE (Urate); Study_ID: I011106,Other,,
913,958603,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: I011106,Other,,
914,958604,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: I011106,Other,,
915,958605,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: S010924,Other,,
916,958606,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: CK (Creatine Kinase); Study_ID: S010924,Other,,
917,958607,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: S010924,Other,,
918,958608,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: S010924,Other,,
919,958609,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: S010924,Other,,
920,958610,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: S010924,Other,,
921,958611,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: S010924,Other,,
922,958612,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: S010924,Other,,
923,958613,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: S010924,Other,,
924,958614,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: S010924,Other,,
925,958615,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: CO2 (Carbon Dioxide); Study_ID: S010924,Other,,
926,958616,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: S010924,Other,,
927,958617,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: S010924,Other,,
928,958618,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: S010924,Other,,
929,958619,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: URATE (Urate); Study_ID: S010924,Other,,
930,958620,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: LIPASE (Triacylglycerol Lipase); Study_ID: S010924,Other,,
931,958621,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: S010924,Other,,
932,958622,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: S010924,Other,,
933,958623,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: S010924,Other,,
934,958624,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 7 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: S010924,Other,,
935,958625,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 7 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: S010924,Other,,
936,958626,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 7 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: CK (Creatine Kinase); Study_ID: S010924,Other,,
937,959198,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 7 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: S010924,Other,,
938,959199,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 7 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: LIPASE (Triacylglycerol Lipase); Study_ID: S010924,Other,,
939,959200,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 7 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: S010924,Other,,
940,959201,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 7 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: S010924,Other,,
941,959202,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 7 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: URATE (Urate); Study_ID: S010924,Other,,
942,959203,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 7 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: CO2 (Carbon Dioxide); Study_ID: S010924,Other,,
943,959204,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 7 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: S010924,Other,,
944,959205,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 7 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: S010924,Other,,
945,959206,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 7 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: S010924,Other,,
946,959207,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 7 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: S010924,Other,,
947,959208,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 7 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: S010924,Other,,
948,959209,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 7 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: S010924,Other,,
949,959210,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 7 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: S010924,Other,,
950,959211,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 7 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: S010924,Other,,
951,959212,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 7 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: S010924,Other,,
952,959213,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 7 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: S010924,Other,,
953,968453,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: S010924,Other,,
954,968454,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: S010924,Other,,
955,968455,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: S010924,Other,,
956,968456,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: S010924,Other,,
957,968457,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: I011106,Other,,
958,968458,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: I011106,Other,,
959,968459,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: I011106,Other,,
960,968460,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: I011106,Other,,
961,968461,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: LIPASE (Triacylglycerol Lipase); Study_ID: I011106,Other,,
962,968462,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: I011106,Other,,
963,968463,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: I011106,Other,,
964,968464,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: I011106,Other,,
965,968465,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: I011106,Other,,
966,968466,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: I011106,Other,,
967,968467,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: I011106,Other,,
968,968468,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: I011106,Other,,
969,968469,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: I011106,Other,,
970,968470,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: I011106,Other,,
971,968471,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: CO2 (Carbon Dioxide); Study_ID: I011106,Other,,
972,968472,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: I011106,Other,,
973,968473,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: I011106,Other,,
974,968474,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: CK (Creatine Kinase); Study_ID: I011106,Other,,
975,968475,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: URATE (Urate); Study_ID: I011106,Other,,
976,971100,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: S010924,Other,,
977,971101,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: S010924,Other,,
978,971102,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: S010924,Other,,
979,971103,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: S010924,Other,,
980,971104,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: S010924,Other,,
981,971105,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: S010924,Other,,
982,971106,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: LIPASE (Triacylglycerol Lipase); Study_ID: S010924,Other,,
983,971107,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: S010924,Other,,
984,971108,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: S010924,Other,,
985,971109,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: URATE (Urate); Study_ID: S010924,Other,,
986,971110,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: S010924,Other,,
987,971111,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: CO2 (Carbon Dioxide); Study_ID: S010924,Other,,
988,971112,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: S010924,Other,,
989,971113,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: S010924,Other,,
990,971114,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: S010924,Other,,
991,971115,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: S010924,Other,,
992,971116,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: S010924,Other,,
993,971117,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: S010924,Other,,
994,971118,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: CK (Creatine Kinase); Study_ID: S010924,Other,,
995,971119,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: I011106,Other,,
996,971120,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: LIPASE (Triacylglycerol Lipase); Study_ID: I011106,Other,,
997,973142,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: URATE (Urate); Study_ID: I011106,Other,,
998,973143,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: I011106,Other,,
999,973144,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: I011106,Other,,
1000,973776,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: I011106,Other,,
1001,973777,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: I011106,Other,,
1002,973778,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: I011106,Other,,
1003,973779,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: CO2 (Carbon Dioxide); Study_ID: I011106,Other,,
1004,973780,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: I011106,Other,,
1005,973781,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: I011106,Other,,
1006,973782,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: I011106,Other,,
1007,973783,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: I011106,Other,,
1008,973784,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: I011106,Other,,
1009,973785,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: I011106,Other,,
1010,973786,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: I011106,Other,,
1011,973787,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: I011106,Other,,
1012,973788,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: I011106,Other,,
1013,973789,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: CK (Creatine Kinase); Study_ID: I011106,Other,,
1014,973790,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: S010924,Other,,
1015,973791,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: S010924,Other,,
1016,973792,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: S010924,Other,,
1017,973793,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: LIPASE (Triacylglycerol Lipase); Study_ID: S010924,Other,,
1018,973794,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: S010924,Other,,
1019,973795,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: S010924,Other,,
1020,973796,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: S010924,Other,,
1021,973797,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: S010924,Other,,
1022,973798,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: S010924,Other,,
1023,973799,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: S010924,Other,,
1024,973800,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: CK (Creatine Kinase); Study_ID: S010924,Other,,
1025,973801,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: S010924,Other,,
1026,973802,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: URATE (Urate); Study_ID: S010924,Other,,
1027,973803,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: S010924,Other,,
1028,973804,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: S010924,Other,,
1029,973805,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: CO2 (Carbon Dioxide); Study_ID: S010924,Other,,
1030,973806,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: S010924,Other,,
1031,973807,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: S010924,Other,,
1032,973808,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: S010924,Other,,
1033,973809,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: S010924,Other,,
1034,973810,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: S010924,Other,,
1035,973811,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: S010924,Other,,
1036,973812,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: S010924,Other,,
1037,973813,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: S010924,Other,,
1038,973814,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: S010924,Other,,
1039,973815,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: S010924,Other,,
1040,973816,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: S010924,Other,,
1041,973817,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: CO2 (Carbon Dioxide); Study_ID: S010924,Other,,
1042,976471,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: CK (Creatine Kinase); Study_ID: S010924,Other,,
1043,976472,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: S010924,Other,,
1044,976473,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: S010924,Other,,
1045,976474,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: S010924,Other,,
1046,976475,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: S010924,Other,,
1047,976476,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: S010924,Other,,
1048,976477,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: LIPASE (Triacylglycerol Lipase); Study_ID: S010924,Other,,
1049,976478,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: S010924,Other,,
1050,976479,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: S010924,Other,,
1051,976480,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: URATE (Urate); Study_ID: S010924,Other,,
1052,976481,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: CK (Creatine Kinase); Study_ID: I011106,Other,,
1053,976482,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: I011106,Other,,
1054,976483,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: I011106,Other,,
1055,976484,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: I011106,Other,,
1056,976485,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: I011106,Other,,
1057,976486,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: I011106,Other,,
1058,976487,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: I011106,Other,,
1059,976488,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: I011106,Other,,
1060,976489,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: I011106,Other,,
1061,976490,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: I011106,Other,,
1062,976491,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: LIPASE (Triacylglycerol Lipase); Study_ID: I011106,Other,,
1063,976492,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: I011106,Other,,
1064,976493,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: I011106,Other,,
1065,976494,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: CO2 (Carbon Dioxide); Study_ID: I011106,Other,,
1066,976495,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: I011106,Other,,
1067,976496,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: I011106,Other,,
1068,976497,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: I011106,Other,,
1069,976498,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: I011106,Other,,
1070,976499,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: URATE (Urate); Study_ID: I011106,Other,,
1071,976500,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: S010924,Other,,
1072,976501,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: CK (Creatine Kinase); Study_ID: S010924,Other,,
1073,976502,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: S010924,Other,,
1074,976503,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: LIPASE (Triacylglycerol Lipase); Study_ID: S010924,Other,,
1075,976504,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: S010924,Other,,
1076,976505,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: S010924,Other,,
1077,976506,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: URATE (Urate); Study_ID: S010924,Other,,
1078,976507,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: S010924,Other,,
1079,977138,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: S010924,Other,,
1080,977139,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: S010924,Other,,
1081,977140,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: CO2 (Carbon Dioxide); Study_ID: S010924,Other,,
1082,977141,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: S010924,Other,,
1083,977142,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: S010924,Other,,
1084,977143,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: S010924,Other,,
1085,977144,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: S010924,Other,,
1086,996513,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Dilatation; Study_ID: S010924,Other,,
1087,996514,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Mesothelial Cell, Hyperplasia; Study_ID: S010924",Other,,
1088,996515,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular Fibrosis; Study_ID: S010924,Other,,
1089,996516,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Atrophy; Study_ID: S010924",Other,,
1090,997100,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Cytoplasm, Eosinophilia; Study_ID: S010924",Other,,
1091,997101,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Degeneration; Study_ID: S010924",Other,,
1092,997102,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Mineralization; Study_ID: S010924",Other,,
1093,997103,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Oncocytic; Study_ID: S010924",Other,,
1094,997104,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Glycogen Accumulation; Study_ID: S010924",Other,,
1095,997105,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Necrosis, Apoptotic; Study_ID: S010924",Other,,
1096,997106,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Subcapsular, Mineralization; Study_ID: S010924",Other,,
1097,997107,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Extramedullary Hematopoiesis; Study_ID: S010924",Other,,
1098,997108,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S010924",Other,,
1099,997109,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Diffuse, Cytoplasm, Eosinophilia; Study_ID: S010924",Other,,
1100,997110,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Lipid Accumulation, Macrovesicular; Study_ID: S010924",Other,,
1101,997111,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Lipid Accumulation, Microvesicular; Study_ID: S010924",Other,,
1102,997112,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Necrosis, Apoptotic; Study_ID: S010924",Other,,
1103,997113,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Increased Mitoses; Study_ID: S010924",Other,,
1104,997114,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Microvesicular; Study_ID: S010924",Other,,
1105,997115,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Apoptotic; Study_ID: S010924",Other,,
1106,997116,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Hypertrophy; Study_ID: S010924",Other,,
1107,997117,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Lipid Accumulation, Macrovesicular; Study_ID: S010924",Other,,
1108,997118,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Single Hepatocyte Necrosis; Study_ID: S010924,Other,,
1109,997119,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Hyperplasia; Study_ID: S010924,Other,,
1110,997120,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Hypertrophy; Study_ID: S010924",Other,,
1111,997121,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Macrovesicular; Study_ID: S010924",Other,,
1112,997122,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S010924",Other,,
1113,997123,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Fibrosis; Study_ID: S010924",Other,,
1114,997124,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nuclear Cytoplasmic Condensation; Study_ID: S010924,Other,,
1115,997125,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S010924",Other,,
1116,997126,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Microvesicular; Study_ID: S010924",Other,,
1117,997127,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Necrosis, Apoptotic; Study_ID: S010924",Other,,
1118,997128,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Necrosis, Oncocytic; Study_ID: S010924",Other,,
1119,997129,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Multinucleated; Study_ID: S010924",Other,,
1120,997130,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Malignant Lymphoma; Study_ID: S010924,Other,,
1121,997131,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Neutrophilic; Study_ID: S010924",Other,,
1122,997132,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Degeneration; Study_ID: S010924",Other,,
1123,997133,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Lipid Accumulation, Microvesicular; Study_ID: S010924",Other,,
1124,997134,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Oval Cell, Hyperplasia; Study_ID: S010924",Other,,
1125,997135,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Subcapsular, Fibrosis; Study_ID: S010924",Other,,
1126,999577,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Thrombus; Study_ID: S010924",Other,,
1127,999578,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Clear Cell Focus; Study_ID: S010924,Other,,
1128,999579,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Cytoplasm, Eosinophilia; Study_ID: S010924",Other,,
1129,999580,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Granulomatous; Study_ID: S010924",Other,,
1130,999581,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Autolysis; Study_ID: S010924,Other,,
1131,999582,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct, Necrosis, Oncocytic; Study_ID: S010924",Other,,
1132,999583,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Glycogen Accumulation; Study_ID: S010924",Other,,
1133,999584,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Macrovesicular; Study_ID: S010924",Other,,
1134,999585,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Necrosis, Oncocytic; Study_ID: S010924",Other,,
1135,999586,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Necrosis, Oncocytic; Study_ID: S010924",Other,,
1136,999587,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Edema; Study_ID: S010924",Other,,
1137,999588,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S010924",Other,,
1138,999589,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 7 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S010924",Other,,
1139,999590,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 7 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Diffuse, Hypertrophy; Study_ID: S010924",Other,,
1140,999591,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 7 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Erythrophagocytosis; Study_ID: S010924",Other,,
1141,999592,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 7 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Glycogen Accumulation; Study_ID: S010924",Other,,
1142,999593,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 7 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Subcapsular, Necrosis, Oncocytic; Study_ID: S010924",Other,,
1143,999594,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 7 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S010924",Other,,
1144,999595,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 7 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Dilatation; Study_ID: S010924,Other,,
1145,999596,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 7 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Mesothelial Cell, Hyperplasia; Study_ID: S010924",Other,,
1146,999597,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 7 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular Fibrosis; Study_ID: S010924,Other,,
1147,999598,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 7 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Atrophy; Study_ID: S010924",Other,,
1148,999599,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 7 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Cytoplasm, Eosinophilia; Study_ID: S010924",Other,,
1149,999600,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 7 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Degeneration; Study_ID: S010924",Other,,
1150,999601,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 7 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Mineralization; Study_ID: S010924",Other,,
1151,999602,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 7 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Oncocytic; Study_ID: S010924",Other,,
1152,999603,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 7 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Glycogen Accumulation; Study_ID: S010924",Other,,
1153,999604,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 7 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Necrosis, Apoptotic; Study_ID: S010924",Other,,
1154,999605,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 7 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Subcapsular, Mineralization; Study_ID: S010924",Other,,
1155,999606,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 7 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Extramedullary Hematopoiesis; Study_ID: S010924",Other,,
1156,999607,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 7 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S010924",Other,,
1157,999608,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 7 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S010924",Other,,
1158,999609,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 7 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Diffuse, Cytoplasm, Eosinophilia; Study_ID: S010924",Other,,
1159,999610,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 7 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Lipid Accumulation, Macrovesicular; Study_ID: S010924",Other,,
1160,999611,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 7 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Lipid Accumulation, Microvesicular; Study_ID: S010924",Other,,
1161,999612,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 7 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Necrosis, Apoptotic; Study_ID: S010924",Other,,
1162,999613,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 7 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Increased Mitoses; Study_ID: S010924",Other,,
1163,999614,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 7 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Microvesicular; Study_ID: S010924",Other,,
1164,1000195,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 7 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Apoptotic; Study_ID: S010924",Other,,
1165,1000196,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 7 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Hypertrophy; Study_ID: S010924",Other,,
1166,1002056,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 7 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Lipid Accumulation, Macrovesicular; Study_ID: S010924",Other,,
1167,1002057,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 7 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Single Hepatocyte Necrosis; Study_ID: S010924,Other,,
1168,1002058,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 7 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Hyperplasia; Study_ID: S010924,Other,,
1169,1002059,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 7 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Hypertrophy; Study_ID: S010924",Other,,
1170,1002060,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 7 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Macrovesicular; Study_ID: S010924",Other,,
1171,1002061,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 7 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S010924",Other,,
1172,1002062,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 7 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Fibrosis; Study_ID: S010924",Other,,
1173,1002063,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 7 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nuclear Cytoplasmic Condensation; Study_ID: S010924,Other,,
1174,1002064,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 7 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S010924",Other,,
1175,1002065,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 7 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Microvesicular; Study_ID: S010924",Other,,
1176,1002066,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 7 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Necrosis, Apoptotic; Study_ID: S010924",Other,,
1177,1002067,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 7 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Necrosis, Oncocytic; Study_ID: S010924",Other,,
1178,1002068,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 7 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Multinucleated; Study_ID: S010924",Other,,
1179,1002069,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 7 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Malignant Lymphoma; Study_ID: S010924,Other,,
1180,1002070,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 7 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S010924",Other,,
1181,1002071,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 7 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Neutrophilic; Study_ID: S010924",Other,,
1182,1002072,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 7 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Degeneration; Study_ID: S010924",Other,,
1183,1002073,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 7 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Lipid Accumulation, Microvesicular; Study_ID: S010924",Other,,
1184,1002074,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 7 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Oval Cell, Hyperplasia; Study_ID: S010924",Other,,
1185,1002075,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 7 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Subcapsular, Fibrosis; Study_ID: S010924",Other,,
1186,1002076,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 7 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Thrombus; Study_ID: S010924",Other,,
1187,1002077,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 7 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Clear Cell Focus; Study_ID: S010924,Other,,
1188,1002078,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 7 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Cytoplasm, Eosinophilia; Study_ID: S010924",Other,,
1189,1002079,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 7 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Granulomatous; Study_ID: S010924",Other,,
1190,1002080,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 7 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Autolysis; Study_ID: S010924,Other,,
1191,1002081,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 7 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct, Necrosis, Oncocytic; Study_ID: S010924",Other,,
1192,1002082,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 7 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Glycogen Accumulation; Study_ID: S010924",Other,,
1193,1002083,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 7 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Macrovesicular; Study_ID: S010924",Other,,
1194,1002084,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 7 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Necrosis, Oncocytic; Study_ID: S010924",Other,,
1195,1002085,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 7 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Necrosis, Oncocytic; Study_ID: S010924",Other,,
1196,1002086,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 7 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Edema; Study_ID: S010924",Other,,
1197,1004524,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S010924",Other,,
1198,1004525,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Diffuse, Hypertrophy; Study_ID: S010924",Other,,
1199,1004526,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Erythrophagocytosis; Study_ID: S010924",Other,,
1200,1004527,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Glycogen Accumulation; Study_ID: S010924",Other,,
1201,1004528,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Subcapsular, Necrosis, Oncocytic; Study_ID: S010924",Other,,
1202,1004529,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S010924",Other,,
1203,1004530,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S010924",Other,,
1204,1005855,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Macrovesicular; Study_ID: S010924",Other,,
1205,1005856,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S010924",Other,,
1206,1005857,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Fibrosis; Study_ID: S010924",Other,,
1207,1005858,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nuclear Cytoplasmic Condensation; Study_ID: S010924,Other,,
1208,1005859,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S010924",Other,,
1209,1005860,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Microvesicular; Study_ID: S010924",Other,,
1210,1005861,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Necrosis, Oncocytic; Study_ID: S010924",Other,,
1211,1005862,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Multinucleated; Study_ID: S010924",Other,,
1212,1005863,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Malignant Lymphoma; Study_ID: S010924,Other,,
1213,1005864,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S010924",Other,,
1214,1005865,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Neutrophilic; Study_ID: S010924",Other,,
1215,1005866,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Degeneration; Study_ID: S010924",Other,,
1216,1005867,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Lipid Accumulation, Microvesicular; Study_ID: S010924",Other,,
1217,1005868,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Oval Cell, Hyperplasia; Study_ID: S010924",Other,,
1218,1005869,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Subcapsular, Fibrosis; Study_ID: S010924",Other,,
1219,1005870,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Thrombus; Study_ID: S010924",Other,,
1220,1005871,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Clear Cell Focus; Study_ID: S010924,Other,,
1221,1005872,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Cytoplasm, Eosinophilia; Study_ID: S010924",Other,,
1222,1005873,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Granulomatous; Study_ID: S010924",Other,,
1223,1005874,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Autolysis; Study_ID: S010924,Other,,
1224,1005875,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct, Necrosis, Oncocytic; Study_ID: S010924",Other,,
1225,1005876,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Glycogen Accumulation; Study_ID: S010924",Other,,
1226,1005877,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Macrovesicular; Study_ID: S010924",Other,,
1227,1005878,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Necrosis, Oncocytic; Study_ID: S010924",Other,,
1228,1005879,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Necrosis, Oncocytic; Study_ID: S010924",Other,,
1229,1005880,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Edema; Study_ID: S010924",Other,,
1230,1005901,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Glycogen Accumulation; Study_ID: S010924",Other,,
1231,1005902,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Subcapsular, Necrosis, Oncocytic; Study_ID: S010924",Other,,
1232,1005903,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Dilatation; Study_ID: S010924,Other,,
1233,1005904,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Mesothelial Cell, Hyperplasia; Study_ID: S010924",Other,,
1234,1005905,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular Fibrosis; Study_ID: S010924,Other,,
1235,1005906,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Atrophy; Study_ID: S010924",Other,,
1236,1005907,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Cytoplasm, Eosinophilia; Study_ID: S010924",Other,,
1237,1005908,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Degeneration; Study_ID: S010924",Other,,
1238,1005909,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Mineralization; Study_ID: S010924",Other,,
1239,1005910,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Oncocytic; Study_ID: S010924",Other,,
1240,1005911,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Glycogen Accumulation; Study_ID: S010924",Other,,
1241,1005912,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Necrosis, Apoptotic; Study_ID: S010924",Other,,
1242,1005913,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Subcapsular, Mineralization; Study_ID: S010924",Other,,
1243,1005914,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Extramedullary Hematopoiesis; Study_ID: S010924",Other,,
1244,1005915,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S010924",Other,,
1245,1005916,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S010924",Other,,
1246,1005917,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Necrosis, Apoptotic; Study_ID: S010924",Other,,
1247,1005918,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Diffuse, Cytoplasm, Eosinophilia; Study_ID: S010924",Other,,
1248,1005919,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Lipid Accumulation, Macrovesicular; Study_ID: S010924",Other,,
1249,1005920,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Lipid Accumulation, Microvesicular; Study_ID: S010924",Other,,
1250,1005921,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Necrosis, Apoptotic; Study_ID: S010924",Other,,
1251,1005922,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Increased Mitoses; Study_ID: S010924",Other,,
1252,1005923,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Microvesicular; Study_ID: S010924",Other,,
1253,1005924,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Apoptotic; Study_ID: S010924",Other,,
1254,1005925,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Hypertrophy; Study_ID: S010924",Other,,
1255,1005926,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Lipid Accumulation, Macrovesicular; Study_ID: S010924",Other,,
1256,1005927,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Single Hepatocyte Necrosis; Study_ID: S010924,Other,,
1257,1005928,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Hyperplasia; Study_ID: S010924,Other,,
1258,1005929,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Hypertrophy; Study_ID: S010924",Other,,
1259,1005930,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Macrovesicular; Study_ID: S010924",Other,,
1260,1005931,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S010924",Other,,
1261,1005932,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Fibrosis; Study_ID: S010924",Other,,
1262,1006513,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nuclear Cytoplasmic Condensation; Study_ID: S010924,Other,,
1263,1006514,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S010924",Other,,
1264,1006515,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Microvesicular; Study_ID: S010924",Other,,
1265,1006516,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Necrosis, Oncocytic; Study_ID: S010924",Other,,
1266,1006517,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Multinucleated; Study_ID: S010924",Other,,
1267,1006518,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Malignant Lymphoma; Study_ID: S010924,Other,,
1268,1006519,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S010924",Other,,
1269,1006520,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Neutrophilic; Study_ID: S010924",Other,,
1270,1007740,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S010924",Other,,
1271,1007741,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Macrovesicular; Study_ID: S010924",Other,,
1272,1007742,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Diffuse, Hypertrophy; Study_ID: S010924",Other,,
1273,1007743,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Erythrophagocytosis; Study_ID: S010924",Other,,
1274,1007744,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Glycogen Accumulation; Study_ID: S010924",Other,,
1275,1007745,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Subcapsular, Necrosis, Oncocytic; Study_ID: S010924",Other,,
1276,1007746,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S010924",Other,,
1277,1007747,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Dilatation; Study_ID: S010924,Other,,
1278,1007748,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Mesothelial Cell, Hyperplasia; Study_ID: S010924",Other,,
1279,1008334,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular Fibrosis; Study_ID: S010924,Other,,
1280,1008335,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Atrophy; Study_ID: S010924",Other,,
1281,1008336,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Cytoplasm, Eosinophilia; Study_ID: S010924",Other,,
1282,1008337,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Degeneration; Study_ID: S010924",Other,,
1283,1008338,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Mineralization; Study_ID: S010924",Other,,
1284,1008339,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Oncocytic; Study_ID: S010924",Other,,
1285,1008340,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Necrosis, Apoptotic; Study_ID: S010924",Other,,
1286,1008341,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Subcapsular, Mineralization; Study_ID: S010924",Other,,
1287,1008342,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Extramedullary Hematopoiesis; Study_ID: S010924",Other,,
1288,1008343,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S010924",Other,,
1289,1008344,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Necrosis, Apoptotic; Study_ID: S010924",Other,,
1290,1008345,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Diffuse, Cytoplasm, Eosinophilia; Study_ID: S010924",Other,,
1291,1008346,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Lipid Accumulation, Macrovesicular; Study_ID: S010924",Other,,
1292,1008347,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Lipid Accumulation, Microvesicular; Study_ID: S010924",Other,,
1293,1008348,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Necrosis, Apoptotic; Study_ID: S010924",Other,,
1294,1008349,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Increased Mitoses; Study_ID: S010924",Other,,
1295,1008350,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Microvesicular; Study_ID: S010924",Other,,
1296,1008351,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Apoptotic; Study_ID: S010924",Other,,
1297,1008352,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Hypertrophy; Study_ID: S010924",Other,,
1298,1008353,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Lipid Accumulation, Macrovesicular; Study_ID: S010924",Other,,
1299,1008354,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Single Hepatocyte Necrosis; Study_ID: S010924,Other,,
1300,1008355,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Hyperplasia; Study_ID: S010924,Other,,
1301,1008356,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Hypertrophy; Study_ID: S010924",Other,,
1302,1008357,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Macrovesicular; Study_ID: S010924",Other,,
1303,1008358,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S010924",Other,,
1304,1008359,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Fibrosis; Study_ID: S010924",Other,,
1305,1008360,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nuclear Cytoplasmic Condensation; Study_ID: S010924,Other,,
1306,1008361,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S010924",Other,,
1307,1008362,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Microvesicular; Study_ID: S010924",Other,,
1308,1008363,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Necrosis, Oncocytic; Study_ID: S010924",Other,,
1309,1008364,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Multinucleated; Study_ID: S010924",Other,,
1310,1008385,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Degeneration; Study_ID: S010924",Other,,
1311,1008386,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Lipid Accumulation, Microvesicular; Study_ID: S010924",Other,,
1312,1008387,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S010924",Other,,
1313,1008388,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Oval Cell, Hyperplasia; Study_ID: S010924",Other,,
1314,1008389,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Subcapsular, Fibrosis; Study_ID: S010924",Other,,
1315,1008390,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Thrombus; Study_ID: S010924",Other,,
1316,1008391,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Clear Cell Focus; Study_ID: S010924,Other,,
1317,1008392,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Cytoplasm, Eosinophilia; Study_ID: S010924",Other,,
1318,1008393,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Granulomatous; Study_ID: S010924",Other,,
1319,1008394,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Autolysis; Study_ID: S010924,Other,,
1320,1008395,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct, Necrosis, Oncocytic; Study_ID: S010924",Other,,
1321,1008396,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Glycogen Accumulation; Study_ID: S010924",Other,,
1322,1008397,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Macrovesicular; Study_ID: S010924",Other,,
1323,1008398,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Necrosis, Oncocytic; Study_ID: S010924",Other,,
1324,1008399,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Necrosis, Oncocytic; Study_ID: S010924",Other,,
1325,1008400,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Edema; Study_ID: S010924",Other,,
1326,1010228,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Malignant Lymphoma; Study_ID: S010924,Other,,
1327,1010229,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Neutrophilic; Study_ID: S010924",Other,,
1328,1010230,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Degeneration; Study_ID: S010924",Other,,
1329,1010231,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Lipid Accumulation, Microvesicular; Study_ID: S010924",Other,,
1330,1010813,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S010924",Other,,
1331,1010814,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Oval Cell, Hyperplasia; Study_ID: S010924",Other,,
1332,1010815,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Subcapsular, Fibrosis; Study_ID: S010924",Other,,
1333,1010816,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Thrombus; Study_ID: S010924",Other,,
1334,1010817,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Clear Cell Focus; Study_ID: S010924,Other,,
1335,1010818,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Cytoplasm, Eosinophilia; Study_ID: S010924",Other,,
1336,1010819,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Glycogen Accumulation; Study_ID: S010924",Other,,
1337,1010820,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Granulomatous; Study_ID: S010924",Other,,
1338,1010821,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Autolysis; Study_ID: S010924,Other,,
1339,1010822,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct, Necrosis, Oncocytic; Study_ID: S010924",Other,,
1340,1010823,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Glycogen Accumulation; Study_ID: S010924",Other,,
1341,1010824,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Necrosis, Oncocytic; Study_ID: S010924",Other,,
1342,1010825,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Necrosis, Oncocytic; Study_ID: S010924",Other,,
1343,1010826,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Edema; Study_ID: S010924",Other,,
1344,1010827,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S010924",Other,,
1345,1010828,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S010924",Other,,
1346,1010829,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Diffuse, Hypertrophy; Study_ID: S010924",Other,,
1347,1010830,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Erythrophagocytosis; Study_ID: S010924",Other,,
1348,1010831,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Glycogen Accumulation; Study_ID: S010924",Other,,
1349,1010832,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Subcapsular, Necrosis, Oncocytic; Study_ID: S010924",Other,,
1350,1010833,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S010924",Other,,
1351,1010834,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Dilatation; Study_ID: S010924,Other,,
1352,1010835,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Mesothelial Cell, Hyperplasia; Study_ID: S010924",Other,,
1353,1010836,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular Fibrosis; Study_ID: S010924,Other,,
1354,1010837,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Atrophy; Study_ID: S010924",Other,,
1355,1010838,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Cytoplasm, Eosinophilia; Study_ID: S010924",Other,,
1356,1010839,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Mineralization; Study_ID: S010924",Other,,
1357,1010840,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Oncocytic; Study_ID: S010924",Other,,
1358,1010841,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Glycogen Accumulation; Study_ID: S010924",Other,,
1359,1010842,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Necrosis, Apoptotic; Study_ID: S010924",Other,,
1360,1010843,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Subcapsular, Mineralization; Study_ID: S010924",Other,,
1361,1010844,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Extramedullary Hematopoiesis; Study_ID: S010924",Other,,
1362,1010845,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S010924",Other,,
1363,1010846,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S010924",Other,,
1364,1010847,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Necrosis, Apoptotic; Study_ID: S010924",Other,,
1365,1010848,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Diffuse, Cytoplasm, Eosinophilia; Study_ID: S010924",Other,,
1366,1010849,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Lipid Accumulation, Macrovesicular; Study_ID: S010924",Other,,
1367,1013264,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S010924",Other,,
1368,1013265,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Diffuse, Hypertrophy; Study_ID: S010924",Other,,
1369,1013266,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Erythrophagocytosis; Study_ID: S010924",Other,,
1370,1013267,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Glycogen Accumulation; Study_ID: S010924",Other,,
1371,1013268,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Subcapsular, Necrosis, Oncocytic; Study_ID: S010924",Other,,
1372,1013269,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S010924",Other,,
1373,1013270,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Dilatation; Study_ID: S010924,Other,,
1374,1013271,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Mesothelial Cell, Hyperplasia; Study_ID: S010924",Other,,
1375,1013272,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular Fibrosis; Study_ID: S010924,Other,,
1376,1013273,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Atrophy; Study_ID: S010924",Other,,
1377,1013274,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Cytoplasm, Eosinophilia; Study_ID: S010924",Other,,
1378,1013275,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Degeneration; Study_ID: S010924",Other,,
1379,1013276,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Mineralization; Study_ID: S010924",Other,,
1380,1013277,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Oncocytic; Study_ID: S010924",Other,,
1381,1013278,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Glycogen Accumulation; Study_ID: S010924",Other,,
1382,1013279,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Necrosis, Apoptotic; Study_ID: S010924",Other,,
1383,1013280,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Subcapsular, Mineralization; Study_ID: S010924",Other,,
1384,1013281,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Extramedullary Hematopoiesis; Study_ID: S010924",Other,,
1385,1013282,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S010924",Other,,
1386,1013301,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Lipid Accumulation, Microvesicular; Study_ID: S010924",Other,,
1387,1013302,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Necrosis, Apoptotic; Study_ID: S010924",Other,,
1388,1013303,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Increased Mitoses; Study_ID: S010924",Other,,
1389,1013304,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Microvesicular; Study_ID: S010924",Other,,
1390,1013305,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Apoptotic; Study_ID: S010924",Other,,
1391,1013306,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Hypertrophy; Study_ID: S010924",Other,,
1392,1013307,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Lipid Accumulation, Macrovesicular; Study_ID: S010924",Other,,
1393,1013308,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Single Hepatocyte Necrosis; Study_ID: S010924,Other,,
1394,1013309,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Hyperplasia; Study_ID: S010924,Other,,
1395,1013310,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Hypertrophy; Study_ID: S010924",Other,,
1396,1013311,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Macrovesicular; Study_ID: S010924",Other,,
1397,1013312,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S010924",Other,,
1398,1013313,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Fibrosis; Study_ID: S010924",Other,,
1399,1013314,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nuclear Cytoplasmic Condensation; Study_ID: S010924,Other,,
1400,1013315,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S010924",Other,,
1401,1013316,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Microvesicular; Study_ID: S010924",Other,,
1402,1013317,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Necrosis, Oncocytic; Study_ID: S010924",Other,,
1403,1013318,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Degeneration; Study_ID: S010924",Other,,
1404,1013319,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Multinucleated; Study_ID: S010924",Other,,
1405,1013320,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Malignant Lymphoma; Study_ID: S010924,Other,,
1406,1013321,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S010924",Other,,
1407,1013322,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Neutrophilic; Study_ID: S010924",Other,,
1408,1013323,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Degeneration; Study_ID: S010924",Other,,
1409,1013324,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Lipid Accumulation, Microvesicular; Study_ID: S010924",Other,,
1410,1013325,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Oval Cell, Hyperplasia; Study_ID: S010924",Other,,
1411,1013326,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Subcapsular, Fibrosis; Study_ID: S010924",Other,,
1412,1013327,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Thrombus; Study_ID: S010924",Other,,
1413,1013328,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Clear Cell Focus; Study_ID: S010924,Other,,
1414,1013329,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Cytoplasm, Eosinophilia; Study_ID: S010924",Other,,
1415,1013330,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Granulomatous; Study_ID: S010924",Other,,
1416,1013331,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Autolysis; Study_ID: S010924,Other,,
1417,1013332,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct, Necrosis, Oncocytic; Study_ID: S010924",Other,,
1418,1013333,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Glycogen Accumulation; Study_ID: S010924",Other,,
1419,1013334,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Macrovesicular; Study_ID: S010924",Other,,
1420,1013335,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Necrosis, Oncocytic; Study_ID: S010924",Other,,
1421,1013336,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Necrosis, Oncocytic; Study_ID: S010924",Other,,
1422,1013337,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Edema; Study_ID: S010924",Other,,
1423,1013338,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S010924",Other,,
1424,1013922,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Diffuse, Hypertrophy; Study_ID: S010924",Other,,
1425,1013923,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Erythrophagocytosis; Study_ID: S010924",Other,,
1426,1015150,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S010924",Other,,
1427,1015151,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Necrosis, Apoptotic; Study_ID: S010924",Other,,
1428,1015152,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Diffuse, Cytoplasm, Eosinophilia; Study_ID: S010924",Other,,
1429,1015153,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Lipid Accumulation, Macrovesicular; Study_ID: S010924",Other,,
1430,1015154,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Lipid Accumulation, Microvesicular; Study_ID: S010924",Other,,
1431,1015155,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Necrosis, Apoptotic; Study_ID: S010924",Other,,
1432,1015156,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Increased Mitoses; Study_ID: S010924",Other,,
1433,1015157,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Microvesicular; Study_ID: S010924",Other,,
1434,1015158,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Apoptotic; Study_ID: S010924",Other,,
1435,1015159,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Hypertrophy; Study_ID: S010924",Other,,
1436,1015160,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Lipid Accumulation, Macrovesicular; Study_ID: S010924",Other,,
1437,1015161,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Single Hepatocyte Necrosis; Study_ID: S010924,Other,,
1438,1015162,1,3,,103168637,6228,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Hyperplasia; Study_ID: S010924,Other,,
1439,1015163,1,3,,103168637,6228,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Hypertrophy; Study_ID: S010924",Other,,
1440,1071716,1,1,,103168637,6228,Unspecified,,,,,Antimicrobial activity against Aspergillus viridinutans at 250 ug/disc after 5 to 7 days by well diffusion method,Other,24486419.0,
1441,1071717,1,1,,103168637,6228,Unspecified,,,,,Antimicrobial activity against Aspergillus niger at 250 ug/disc after 5 to 7 days by well diffusion method,Other,24486419.0,
1442,1071718,1,1,,103168637,6228,Unspecified,,,,,Antimicrobial activity against Escherichia coli at 250 ug/disc after 48 hrs by well diffusion method,Other,24486419.0,
1443,1071719,1,1,,103168637,6228,Unspecified,,,,,Antimicrobial activity against Bacillus subtilis at 250 ug/disc after 48 hrs by well diffusion method,Other,24486419.0,
1444,1094036,1,2,,103168637,6228,Unspecified,,,,,Antifungal activity against Candida albicans MTCC 227 after 2 to 3 days by cup-plate method,Other,,
1445,1094037,1,2,,103168637,6228,Unspecified,,,,,Antifungal activity against Fusarium oxysporum after 2 to 3 days by cup-plate method,Other,,
1446,1094038,1,2,,103168637,6228,Unspecified,,,,,Antifungal activity against Aspergillus niger MTCC 1344 after 2 to 3 days by cup-plate method,Other,,
1447,1094039,1,2,,103168637,6228,Unspecified,,,,,Antibacterial activity against Escherichia coli MTCC 40 assessed as inhibition of growth zone at 20 ug/ml after 24 hr by cup-plate method relative to norfloxacin,Other,,
1448,1094040,1,2,,103168637,6228,Unspecified,,,,,Antibacterial activity against Pseudomonas aeruginosa MTCC 424 assessed as inhibition of growth zone at 20 ug/ml after 24 hr by cup-plate method relative to norfloxacin,Other,,
1449,1094041,1,2,,103168637,6228,Unspecified,,,,,Antibacterial activity against Bacillus subtilis MTCC 619 assessed as inhibition of growth zone at 20 ug/ml after 24 hr by cup-plate method relative to norfloxacin,Other,,
1450,1094042,1,2,,103168637,6228,Unspecified,,,,,Antibacterial activity against Staphylococcus aureus MTCC 96 assessed as inhibition of growth zone at 20 ug/ml after 24 hr by cup-plate method relative to norfloxacin,Other,,
1451,1094043,1,2,,103168637,6228,Unspecified,,,,,Antibacterial activity against Escherichia coli MTCC 40 after 24 hr by cup-plate method,Other,,
1452,1094044,1,2,,103168637,6228,Unspecified,,,,,Antibacterial activity against Pseudomonas aeruginosa MTCC 424 after 24 hr by cup-plate method,Other,,
1453,1094045,1,2,,103168637,6228,Unspecified,,,,,Antibacterial activity against Bacillus subtilis MTCC 619 after 24 hr by cup-plate method,Other,,
1454,1094046,1,2,,103168637,6228,Unspecified,,,,,Antibacterial activity against Staphylococcus aureus MTCC 96 after 24 hr by cup-plate method,Other,,
1455,1159509,1,1,,144208457,6228,Inactive,119626539.0,4790.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway,Confirmatory,,
1456,1159509,1,1,,144210359,6228,Inactive,119626539.0,4790.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway,Confirmatory,,
1457,1159515,1,1,,144208457,6228,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway - cell viability counter screen,Confirmatory,,
1458,1159515,1,1,,144210359,6228,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway - cell viability counter screen,Confirmatory,,
1459,1159516,1,1,,144208457,6228,Inactive,119611100.0,22926.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway,Confirmatory,,
1460,1159516,1,1,,144210359,6228,Inactive,119611100.0,22926.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway,Confirmatory,,
1461,1159517,1,1,,144208457,6228,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway - cell viability counter screen,Confirmatory,,
1462,1159517,1,1,,144210359,6228,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway - cell viability counter screen,Confirmatory,,
1463,1159518,1,1,,144208457,6228,Inactive,119626539.0,4790.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the NFkB signaling pathway: Summary,Summary,,
1464,1159518,1,1,,144210359,6228,Inactive,119626539.0,4790.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the NFkB signaling pathway: Summary,Summary,,
1465,1159519,1,1,,144208457,6228,Inactive,119611100.0,22926.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway: Summary,Summary,,
1466,1159519,1,1,,144210359,6228,Inactive,119611100.0,22926.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway: Summary,Summary,,
1467,1159520,1,1,,144208457,6228,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway - cell viability counter screen,Confirmatory,,
1468,1159520,1,1,,144210359,6228,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway - cell viability counter screen,Confirmatory,,
1469,1159521,1,1,,144208457,6228,Inactive,15928672.0,19885.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway,Confirmatory,,
1470,1159521,1,1,,144210359,6228,Inactive,15928672.0,19885.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway,Confirmatory,,
1471,1159523,1,1,,144208457,6228,Inactive,15928672.0,19885.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway: Summary,Summary,,
1472,1159523,1,1,,144210359,6228,Inactive,15928672.0,19885.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway: Summary,Summary,,
1473,1159525,1,1,,144208457,6228,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway - cell viability counter screen,Confirmatory,,
1474,1159525,1,1,,144210359,6228,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway - cell viability counter screen,Confirmatory,,
1475,1159526,1,1,,144208457,6228,Inactive,119627033.0,3725.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway,Confirmatory,,
1476,1159526,1,1,,144210359,6228,Inactive,119627033.0,3725.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway,Confirmatory,,
1477,1159527,1,1,,144208457,6228,Inactive,325495497.0,6256.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway,Confirmatory,,
1478,1159527,1,1,,144210359,6228,Inactive,325495497.0,6256.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway,Confirmatory,,
1479,1159528,1,1,,144208457,6228,Inactive,119627033.0,3725.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the AP-1 signaling pathway: Summary,Summary,,
1480,1159528,1,1,,144210359,6228,Inactive,119627033.0,3725.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the AP-1 signaling pathway: Summary,Summary,,
1481,1159529,1,1,,144208457,6228,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway - cell viability counter screen,Confirmatory,,
1482,1159529,1,1,,144210359,6228,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway - cell viability counter screen,Confirmatory,,
1483,1159531,1,1,,144208457,6228,Inactive,325495497.0,6256.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the RXR signaling pathway: Summary,Summary,,
1484,1159531,1,1,,144210359,6228,Inactive,325495497.0,6256.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the RXR signaling pathway: Summary,Summary,,
1485,1159551,1,1,,144208457,6228,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid acid receptor (RAR) signaling pathway - cell viability counter screen,Confirmatory,,
1486,1159551,1,1,,144210359,6228,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid acid receptor (RAR) signaling pathway - cell viability counter screen,Confirmatory,,
1487,1159552,1,1,,144208457,6228,Inactive,325495463.0,5914.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
1488,1159552,1,1,,144210359,6228,Inactive,325495463.0,5914.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
1489,1159553,2,1,,144208457,6228,Inactive,325495463.0,5914.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
1490,1159553,2,1,,144210359,6228,Inactive,325495463.0,5914.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
1491,1159555,1,1,,144208457,6228,Inconclusive,325495463.0,5914.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway: Summary,Summary,,
1492,1159555,1,1,,144210359,6228,Inactive,325495463.0,5914.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway: Summary,Summary,,
1493,1224834,3,1,,144208457,6228,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library - cell viability counter screen,Confirmatory,,
1494,1224834,3,1,,144210359,6228,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library - cell viability counter screen,Confirmatory,,
1495,1224835,1,1,,144208457,6228,Inactive,160794.0,,,Potency-Replicate_1,qHTS assay to identify small molecule inhibitors of firefly luciferase,Confirmatory,,
1496,1224835,1,1,,144210359,6228,Inactive,160794.0,,,Potency-Replicate_1,qHTS assay to identify small molecule inhibitors of firefly luciferase,Confirmatory,,
1497,1224836,1,1,,144208457,6228,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
1498,1224836,1,1,,144210359,6228,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
1499,1224837,1,1,,144208457,6228,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
1500,1224837,1,1,,144210359,6228,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
1501,1224838,1,1,,144208457,6228,Inactive,66775687.0,9970.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
1502,1224838,1,1,,144210359,6228,Inactive,66775687.0,9970.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
1503,1224839,1,1,,144208457,6228,Inactive,66775687.0,9970.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
1504,1224839,1,1,,144210359,6228,Inactive,66775687.0,9970.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
1505,1224840,3,1,,144208457,6228,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library - cell viability counter screen,Confirmatory,,
1506,1224840,3,1,,144210359,6228,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library - cell viability counter screen,Confirmatory,,
1507,1224841,3,1,,144208457,6228,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
1508,1224841,3,1,,144210359,6228,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
1509,1224842,3,1,,144208457,6228,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
1510,1224842,3,1,,144210359,6228,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
1511,1224843,1,1,,144208457,6228,Inactive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
1512,1224843,1,1,,144210359,6228,Inactive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
1513,1224844,1,1,,144208457,6228,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway - cell viability counter screen,Confirmatory,,
1514,1224844,1,1,,144210359,6228,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway - cell viability counter screen,Confirmatory,,
1515,1224845,1,1,,144208457,6228,Inactive,344243002.0,100757539.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX,Confirmatory,,
1516,1224845,1,1,,144210359,6228,Inactive,344243002.0,100757539.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX,Confirmatory,,
1517,1224846,1,1,,144208457,6228,Inactive,11995455.0,3091.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway,Confirmatory,,
1518,1224846,1,1,,144210359,6228,Inactive,11995455.0,3091.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway,Confirmatory,,
1519,1224847,1,1,,144208457,6228,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX - cell viability counter screen,Confirmatory,,
1520,1224847,1,1,,144210359,6228,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX - cell viability counter screen,Confirmatory,,
1521,1224848,3,1,,144208457,6228,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
1522,1224848,3,1,,144210359,6228,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
1523,1224849,3,1,,144208457,6228,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
1524,1224849,3,1,,144210359,6228,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
1525,1224867,1,1,,144208457,6228,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 24 hour,Confirmatory,,
1526,1224867,1,1,,144210359,6228,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 24 hour,Confirmatory,,
1527,1224868,1,1,,144208457,6228,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 32 hour,Confirmatory,,
1528,1224868,1,1,,144210359,6228,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 32 hour,Confirmatory,,
1529,1224869,1,1,,144208457,6228,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 0 hour,Confirmatory,,
1530,1224869,1,1,,144210359,6228,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 0 hour,Confirmatory,,
1531,1224870,1,1,,144208457,6228,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 40 hour,Confirmatory,,
1532,1224870,1,1,,144210359,6228,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 40 hour,Confirmatory,,
1533,1224871,1,1,,144208457,6228,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 40 hour,Confirmatory,,
1534,1224871,1,1,,144210359,6228,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 40 hour,Confirmatory,,
1535,1224872,1,1,,144208457,6228,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 16 hour,Confirmatory,,
1536,1224872,1,1,,144210359,6228,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 16 hour,Confirmatory,,
1537,1224873,1,1,,144208457,6228,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 8 hour,Confirmatory,,
1538,1224873,1,1,,144210359,6228,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 8 hour,Confirmatory,,
1539,1224874,1,1,,144208457,6228,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 40 hour,Confirmatory,,
1540,1224874,1,1,,144210359,6228,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 40 hour,Confirmatory,,
1541,1224875,1,1,,144208457,6228,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 24 hour,Confirmatory,,
1542,1224875,1,1,,144210359,6228,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 24 hour,Confirmatory,,
1543,1224876,1,1,,144208457,6228,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 16 hour,Confirmatory,,
1544,1224876,1,1,,144210359,6228,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 16 hour,Confirmatory,,
1545,1224877,1,1,,144208457,6228,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 32 hour,Confirmatory,,
1546,1224877,1,1,,144210359,6228,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 32 hour,Confirmatory,,
1547,1224878,1,1,,144208457,6228,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 24 hour,Confirmatory,,
1548,1224878,1,1,,144210359,6228,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 24 hour,Confirmatory,,
1549,1224879,1,1,,144208457,6228,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 40 hour,Confirmatory,,
1550,1224879,1,1,,144210359,6228,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 40 hour,Confirmatory,,
1551,1224880,1,1,,144208457,6228,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 0 hour,Confirmatory,,
1552,1224880,1,1,,144210359,6228,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 0 hour,Confirmatory,,
1553,1224881,1,1,,144208457,6228,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 32 hour,Confirmatory,,
1554,1224881,1,1,,144210359,6228,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 32 hour,Confirmatory,,
1555,1224882,1,1,,144208457,6228,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 0 hour,Confirmatory,,
1556,1224882,1,1,,144210359,6228,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 0 hour,Confirmatory,,
1557,1224883,1,1,,144208457,6228,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 32 hour,Confirmatory,,
1558,1224883,1,1,,144210359,6228,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 32 hour,Confirmatory,,
1559,1224884,1,1,,144208457,6228,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 8 hour,Confirmatory,,
1560,1224884,1,1,,144210359,6228,Inconclusive,,,61.6448,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 8 hour,Confirmatory,,
1561,1224885,1,1,,144208457,6228,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 16 hour,Confirmatory,,
1562,1224885,1,1,,144210359,6228,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 16 hour,Confirmatory,,
1563,1224886,1,1,,144208457,6228,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 24 hour,Confirmatory,,
1564,1224886,1,1,,144210359,6228,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 24 hour,Confirmatory,,
1565,1224887,1,1,,144208457,6228,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 8 hour,Confirmatory,,
1566,1224887,1,1,,144210359,6228,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 8 hour,Confirmatory,,
1567,1224888,1,1,,144208457,6228,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 16 hour,Confirmatory,,
1568,1224888,1,1,,144210359,6228,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 16 hour,Confirmatory,,
1569,1224889,1,1,,144208457,6228,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 0 hour,Confirmatory,,
1570,1224889,1,1,,144210359,6228,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 0 hour,Confirmatory,,
1571,1224890,1,1,,144208457,6228,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 8 hour,Confirmatory,,
1572,1224890,1,1,,144210359,6228,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 8 hour,Confirmatory,,
1573,1224892,1,1,,144208457,6228,Inactive,66775687.0,9970.0,,,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
1574,1224892,1,1,,144210359,6228,Inactive,66775687.0,9970.0,,,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
1575,1224893,1,1,,144208457,6228,Inactive,66775687.0,9970.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
1576,1224893,1,1,,144210359,6228,Inactive,66775687.0,9970.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
1577,1224894,1,1,,144208457,6228,Inactive,11995455.0,3091.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway: Summary,Summary,,
1578,1224894,1,1,,144210359,6228,Inactive,11995455.0,3091.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway: Summary,Summary,,
1579,1224895,1,1,,144208457,6228,Inconclusive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
1580,1224895,1,1,,144210359,6228,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
1581,1224896,1,1,,144208457,6228,Inactive,344243002.0,100757539.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of H2AX: Summary,Summary,,
1582,1224896,1,1,,144210359,6228,Inactive,344243002.0,100757539.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of H2AX: Summary,Summary,,
1583,1259241,1,1,,144208457,6228,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol - cell viability counter screen,Confirmatory,,
1584,1259241,1,1,,144210359,6228,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol - cell viability counter screen,Confirmatory,,
1585,1259242,1,1,,144208457,6228,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881 - cell viability counter screen,Confirmatory,,
1586,1259242,1,1,,144210359,6228,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881 - cell viability counter screen,Confirmatory,,
1587,1259243,1,1,,144208457,6228,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881,Confirmatory,,
1588,1259243,1,1,,144210359,6228,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881,Confirmatory,,
1589,1259244,1,1,,144208457,6228,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol,Confirmatory,,
1590,1259244,1,1,,144210359,6228,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol,Confirmatory,,
1591,1259247,1,1,,144208457,6228,Inactive,124375976.0,367.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881: Summary,Summary,,
1592,1259247,1,1,,144210359,6228,Inactive,124375976.0,367.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881: Summary,Summary,,
1593,1259248,1,1,,144208457,6228,Inactive,348019627.0,2099.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol: Summary,Summary,,
1594,1259248,1,1,,144210359,6228,Inactive,348019627.0,2099.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol: Summary,Summary,,
1595,1259364,1,1,,144208457,6228,Inactive,1013403374.0,9734.0,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors,Confirmatory,,
1596,1259364,1,1,,144210359,6228,Inactive,1013403374.0,9734.0,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors,Confirmatory,,
1597,1259365,1,1,,144208457,6228,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors - cell viability counter screen,Confirmatory,,
1598,1259365,1,1,,144210359,6228,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors - cell viability counter screen,Confirmatory,,
1599,1259366,1,1,,144208457,6228,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
1600,1259366,1,1,,144210359,6228,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
1601,1259367,1,1,,144208457,6228,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
1602,1259367,1,1,,144210359,6228,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
1603,1259368,1,1,,144208457,6228,Inactive,109731339.0,2737.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
1604,1259368,1,1,,144210359,6228,Inactive,109731339.0,2737.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
1605,1259369,1,1,,144208457,6228,Inactive,109731339.0,2737.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
1606,1259369,1,1,,144210359,6228,Inactive,109731339.0,2737.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
1607,1259377,1,1,,144208457,6228,Inactive,54288833.0,2100.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
1608,1259377,1,1,,144210359,6228,Inactive,54288833.0,2100.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
1609,1259378,1,1,,144208457,6228,Inactive,54288833.0,2100.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
1610,1259378,1,1,,144210359,6228,Inactive,54288833.0,2100.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
1611,1259379,1,1,,144208457,6228,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
1612,1259379,1,1,,144210359,6228,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
1613,1259380,1,1,,144208457,6228,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
1614,1259380,1,1,,144210359,6228,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
1615,1259381,1,1,,144208457,6228,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist,Confirmatory,,
1616,1259381,1,1,,144210359,6228,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist,Confirmatory,,
1617,1259382,1,1,,144208457,6228,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
1618,1259382,1,1,,144210359,6228,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
1619,1259383,1,1,,144208457,6228,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist,Confirmatory,,
1620,1259383,1,1,,144210359,6228,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist,Confirmatory,,
1621,1259384,1,1,,144208457,6228,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen,Confirmatory,,
1622,1259384,1,1,,144210359,6228,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen,Confirmatory,,
1623,1259385,1,1,,144208457,6228,Inactive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
1624,1259385,1,1,,144210359,6228,Inactive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
1625,1259386,1,1,,144208457,6228,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
1626,1259386,1,1,,144210359,6228,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
1627,1259387,1,1,,144208457,6228,Inactive,124375976.0,367.0,,,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist: Summary,Summary,,
1628,1259387,1,1,,144210359,6228,Inactive,124375976.0,367.0,,,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist: Summary,Summary,,
1629,1259388,1,1,,144208457,6228,Inactive,1013403374.0,9734.0,,Antagonist Potency (uM),qHTS assay to identify small molecule HDAC inhibitors: Summary,Summary,,
1630,1259388,1,1,,144210359,6228,Inactive,1013403374.0,9734.0,,Antagonist Potency (uM),qHTS assay to identify small molecule HDAC inhibitors: Summary,Summary,,
1631,1259390,1,1,,144208457,6228,Inactive,109731339.0,2737.0,,,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
1632,1259390,1,1,,144210359,6228,Inactive,109731339.0,2737.0,,,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
1633,1259391,1,1,,144208457,6228,Inconclusive,348019627.0,2099.0,,,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist: Summary,Summary,,
1634,1259391,1,1,,144210359,6228,Inactive,348019627.0,2099.0,,,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist: Summary,Summary,,
1635,1259392,1,1,,144208457,6228,Inactive,109731339.0,2737.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
1636,1259392,1,1,,144210359,6228,Inactive,109731339.0,2737.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
1637,1259393,1,1,,144208457,6228,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen: Summary,Summary,,
1638,1259393,1,1,,144210359,6228,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen: Summary,Summary,,
1639,1259394,1,1,,144208457,6228,Inactive,54288833.0,2100.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
1640,1259394,1,1,,144210359,6228,Inactive,54288833.0,2100.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
1641,1259395,1,1,,144208457,6228,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
1642,1259395,1,1,,144210359,6228,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
1643,1259396,1,1,,144208457,6228,Inactive,54288833.0,2100.0,,,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
1644,1259396,1,1,,144210359,6228,Inactive,54288833.0,2100.0,,,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
1645,1259401,1,1,,144208457,6228,Inconclusive,325495545.0,2101.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
1646,1259401,1,1,,144210359,6228,Inactive,325495545.0,2101.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
1647,1259402,1,1,,144208457,6228,Inconclusive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
1648,1259402,1,1,,144210359,6228,Inactive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
1649,1259403,1,1,,144208457,6228,Inactive,325495545.0,2101.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
1650,1259403,1,1,,144210359,6228,Inactive,325495545.0,2101.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
1651,1259404,1,1,,144208457,6228,Inactive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
1652,1259404,1,1,,144210359,6228,Inactive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
1653,1259407,1,1,,363899588,6228,Inactive,,,,,CCRIS mutagenicity studies,Other,,
1654,1259408,1,1,,363894956,6228,Inactive,,,,,GENE-TOX mutagenicity studies,Other,,
1655,1259411,1,1,,363899588,6228,Inactive,,,,,CCRIS carcinogenicity studies,Other,,
